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Myocardial infarction (MI), defined as heart damage due to prolonged ischemia, accounts for 
significant mortality and morbidity and has a substantial financial burden worldwide. While 
major advancements have been achieved in the characterization of the JAK/STAT signalling 
pathway in the context of stress and infection, numerous questions on its involvement in 
cardiac dysfunction and remodeling remain unanswered. In this study, ligation of the left 
anterior descending coronary artery (LAD) was performed in wild-type and knock-in mice 
expressing a STAT1 point mutant with defective cooperative DNA binding (STAT1-F77A), 
to address the role of interferon signalling in acute myocardial infarction. We hypothesized 
that mice with dysfunctional STAT1 signalling would show a similar phenotype to mice 
expressing hyperactive STAT3 with respect to its cardioprotective actions. Using 
echocardiographic evaluation and transcriptomic analysis, we found that a loss of STAT1 
tetramerisation protected against adverse cardiac remodeling in female mice. RNA 
sequencing uncovered numerous immune and metabolic pathways that were differentially 
regulated in these mice at day 1 post-myocardial injury. The top five immune-related 
pathways that were upregulated post-MI in both wild-type and F77A mice were cytokine-
cytokine receptor interactions, chemokine signalling pathways, cell adhesion molecules, 
regulation of actin cytoskeleton and leukocyte transendothelial migration, whereas the top 
five metabolism-related pathways downregulated post-MI were oxidative phosphorylation, 
citrate cycle, fatty acid metabolism, fatty acid degradation, and propanoate metabolism in 
both wild-type and STAT1-F77A mice. Gene set enrichment analysis revealed a 
downregulation of cardiac muscle contraction pathway in STAT1-F77A mice only, 
conceivably due to a heterogeneous cell population of infiltrating immune cells in the 
infarcted myocardium. In addition, the distinctive transcriptomic profile of infiltrating 
immune cells in the infarcted area of STAT1-F77A mice was characterized by the 
upregulation of several immune-activating markers to a higher order of magnitude as 
compared to their wild-type littermates, including chemokines and their receptors, adhesion 
molecules, cytokines and their receptors, growth factors and their receptors, coagulation 
cascade proteins, and heat shock proteins. Notably, the top ten genes differentially expressed 
in the infarcted area of STAT1-F77A were Fgf23, Cxcl3, Slfn4, Rab44, Cxcl2, Cd177, 
Gm5483, Il1r2, Cd300lf, and Slfn1. The observed upregulation of genes encoding neutrophil 
markers and adhesion molecules and the significant downregulation of genes engaged in 
oxidative phosphorylation in the STAT1-F77A mouse line as compared to wild-type mice 
may act as an adaptive response to reduce oxidative stress, repair cardiac damage and increase 
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survival. Additionally, in a parallel plate flow chamber assay, STAT1- and STAT3-
knockdown HL-60 cells had reduced transendothelial migration when compared to control 
cells. We conclude that in the early phase of myocardial infarction, a series of transcriptional 
regulations can probably initiate a beneficial remodeling of the left ventricle in a mouse 
model expressing dysfunctional STAT1. This study has expanded our understanding of 






1. Introduction  
Ischemic heart diseases have accounted globally for more than one million deaths in 2017, 
making them the first cause of early death. Myocardial infarction (MI) results from acute 
obstruction of a coronary artery with subsequent myocardial cell death, leading to insufficient 
pumping of blood to meet the body’s demand or what is known as heart failure (Thygesen et al., 
2018). Accumulative research in mechanistic and cellular adaptations to cardiac injury has 
enhanced our understanding of maladaptive cardiac remodeling (Schirone et al., 2017). It is 
largely accepted that ischemic damage to the cardiac tissue is accompanied by sterile 
inflammatory responses, where several cytokines play significant roles (Epelman et al., 2015). 
Until recently, the potential involvement of the JAK/STAT pathway in cardiac repair, 
regeneration and metabolism has remained largely underestimated. Hence, elucidation of the 
JAK/STAT signalling pathway in ischemia-induced cardiac dysfunction is relevant for a 
deeper understanding of the disease outcome. Notably, STAT proteins are known to control a 
remarkable variety of fundamental biological processes, such as cellular proliferation, 
differentiation, growth and homeostasis (Abroun et al., 2015). As transcription factors, STAT 
proteins are characterized by their highly conserved amino acid sequence among different 
species, including nematodes, insects, and vertebrates (Wang and Levy, 2012). STAT1 and 
STAT2 were the first two members of STAT protein family to be discovered, followed by 
five more, namely STAT3, STAT4, STAT5A, STAT5B, and STAT6. Apart from STAT2, all 
human STAT proteins form homodimers (Kisseleva et al., 2002). Additionally, STATs can be 
found in heterodimers, e.g. STAT1:STAT2 and STAT1:STAT3, where the magnitude and 
nature of heterodimeric STATs are influenced by the type of activating ligands (Delgoffe and 
Vignali, 2013). Since the immunological actions of interferons are not restricted to anti-viral 
immunity, the investigation of the JAK/STAT pathway is continuously extending our 
knowledge and generates surprising findings.  
STAT1 knock-out mice have reported profound biological defects in response to type I, II, 
and III interferons and less to other ligands (Akira, 1999). Non-canonical STAT signalling 
exerts transcriptional regulation in mammals (Majoros et al., 2017), where STAT1 and 
STAT3 can regulate gene transcription either through binding to DNA or indirectly by several 
co-activators. Additionally, unphosphorylated STAT3 is known to translocate to the 
mitochondria and interfere with the energy production by changes in the mitochondrial 
cellular respiration (Wegrzyn et al., 2009). This extends further connections that link STATs 





1.1 Discovery of the JAK/STAT signal transduction pathway 
The history of the JAK/STAT signal transduction discovery dates back to the 1980s. At that 
time, research groups led by James Darnell, Ian Kerr, and George Stark were interested in the 
question, how gene transcription could be induced within minutes following type I interferons 
treatment of cells. The rate at which a signal originated at the plasma membrane and 
transduced to activate target genes in the nucleus, proposed the presence of few intermediate 
steps. Utilizing different biochemical and genetic techniques, the Darnell, Kerr and Stark 
laboratories uncovered a previously unrecognized direct signal transduction pathway to the 
nucleus by identifying the STATs as signal transducers and activators of transcription 
(Darnell et al., 1994; Fu et al., 1992). Briefly following this pioneering breakthrough, non-
receptor protein tyrosine kinases (pTK) were separately discovered in signalling pathways 
involving interferons, erythropoietin, and growth hormone receptors (Argetsinger et al., 1993; 
Velazquez et al., 1992; Witthuhn, et al. 1993). Identical kinases had also come into sight 
earlier in screening for new pTKs and were called Janus kinases (Firmbach-Kraft et al., 1990; 
Wilks et al., 1991). Genetic complementation of interferon-unresponsive mutants with 
recombinant JAK and STAT proteins had made it feasible to reconstitute interferon signalling 
between the cell membrane and the transcription machinery in the nucleus, with merely two 
elements: firstly, receptor-associated JAKs that carry the recruitment side for tyrosine 
phosphorylation of STATs as a first step, and secondly, tyrosine-phosphorylated STATs, 
which translocate to the nucleus and activate target genes through binding to specific DNA 
elements (Levy and Darnell, 1990). Currently, the JAK/STAT signal transduction is viewed 
as a key pathway transducing signals to the nucleus from class I and class II cytokine 
receptors. Owing to its immense implication in biology, the JAK/STAT pathway is portrayed 
as a major signalling paradigm (Bousoik et al., 2018). Thus, it is not surprising that JAKs and 
STATs regulate vital processes in the cell, wherein almost every intricate biological process, 
from embryogenesis to aging is affected by the JAK/STAT signal transduction (Binari and 
Perrimon 1994).  
1.1.1 Interferons are categorized as cytokines 
Cytokines are extracellular soluble proteins that convey cell-to-cell signals. They control a 
plethora of intercellular processes and regulate the recruitment of cells that are involved in 
inflammation, cellular growth, proliferation, differentiation, apoptosis, angiogenesis, 
homeostasis, tissue repair, and remodeling. Different families of cytokines bind their cognate 





differentiation and survival (Dinarello, 2007). When classified, they can be grouped by their 
structure and their receptors. One group of cytokines is called interferons (IFNs), which are 
produced as glycoproteins by a variety of cell types to carry important cell signalling events 
and trigger various immune responses (Pestka et al., 2007). Notably, interferons can interfere 
with viral replication, making it less permissive for the virus to replicate inside the cell (Isaacs 
and Lindenmann, 1957). Classification of interferons is based upon their receptors, to which 
they bind to in order to carry the signal inside the cell. For example, interferons type I binds to 
IFNAR (interferon / receptor) which consists of two chains, IFNAR1 ( chain) and 
IFNAR2 ( chain), whereas interferon type II binds to INFGR (interferon- receptor). There 
are many type I interferons, namely IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and 
IFN-ζ, and only one type II interferon, which is IFN-γ (Mesev et al. 2019).  
1.1.2 Structure, function, and regulation of STAT proteins 
The STATs are differentially regulated by a multitude of signalling molecules, including 
interferons, interleukins, growth factors, and hormones (Ihle et al., 1996). The mammalian 
STAT family comprises seven STAT proteins, which are STAT1, STAT2, STAT3, STAT4, 
STAT5a, STAT5b, and STAT6 (Kisseleva et al., 2002). STAT proteins have a size range 
between 750-900 amino acids. Studying the genomic clustering of STATs and searching for 
sequence similarity in other eukaryotic species have led to the identification of homologs 
most closely related to STAT3 and STAT5, in organisms like Dictyostelium (Kawata et al., 
1997), C. elegans (Wang and Levy, 2006), and Drosophila (Zeidler et al., 2000). In contrast 
to Drosophila, where a single STAT transmits the signal through the classical JAK/STAT 
pathway, the homologs in C. elegans and Dictyostelium signal through different pathways.  
 
 
Figure 1: A schematic representation of STAT proteins structure. NH2, N-terminus domain; CCD, 
coiled-coil domain; DBD, DNA-binding domain; LD, linker domain; SH2, Src-homology 2 domain; 
TS: phosphotyrosyl tail with phosphorylation sites; TAD, transactivation domain. 
 
Utilizing multiple sequence alignment models and analyzing the crystal structure have helped 
in the identification of six structurally and functionally conserved domains in STAT proteins 
(Figure 1) (Becker et al., 1998; Chen et al., 1998): (1) The amino terminal domain (NH2) 





homotypic interactions between STAT molecules (Vinkemeier et al., 1998). (2) The coiled-
coil domain, located between 135-315 amino acids, is a four-helix bundle that protrudes 
laterally (~80Å) from the core and associates with a number of potentially important 
regulatory proteins. Hence, it is implicated in nuclear import and export (Begitt et al., 2000). 
(3) The DNA-binding domain (DBD) (320-480 amino acids), recognizes the palindromic 
GAS element in activated STAT homodimers (except STAT2), and participates in the process 
of nuclear import/export (Horvath et al., 1995). (4) The linker domain, localized roughly 
between 480-575 amino acids, is able to structurally translate the dimerization signal to the 
DNA-binding motif and regulate basal nuclear export in resting cells (Hüntelmann et al., 
2014). (5) The SH2 domain, which is between 575-680 amino acids, is the most highly 
conserved motif. This domain mediates the specific recruitment to the appropriate receptor as 
well as the formation of active STAT dimers (Greenlund et al. 1994; Heim et al., 1995). (6) 
The transcriptional activation domain (TAD) is conserved between mouse and man for every 
STAT member except STAT2, however, it diverges substantially between STATs. The TAD 
domain includes conserved serine phosphorylation sites that direct the recruitment of 
coactivators and in some cases regulate STAT stability (Varinou et al., 2003).  
Following phosphorylation of the tyrosine activation motif on the conserved tyrosine residue 
(701), the phosphotyrosyl residue is subsequently recognized by an SH2 domain on other 
STAT protomers leading to the formation of active STAT dimers. The amino terminal domain 
and the SH2 domain are the most conserved structures, they are also involved in protein-
protein interactions, including dimerization, binding to the transcriptional co-activator CREB-
binding protein (CBP/p300), and binding to the cytoplasmic receptor (Wojciak et al., 2009; 
Zhang et al., 1996). The cytoplasmic and nuclear compartment both play an important role in 
modulating the kinetics of STAT activation. While the activation of the JAK/STAT signal 
pathway leads to the formation of dimers in parallel conformation by reciprocal 
phosphotyrosine (pY)-SH2 domain interactions, the antiparallel alignment is present mostly in 
the absence of stimulation. The parallel conformation positions the two phosphorylated 
tyrosine residues in opposing SH2-domain pockets, thus protecting STAT1 from 
dephosphorylation. Therefore, the current notion is that conformational transition from the 
parallel to the antiparallel alignment renders the phosphotyrosine residue susceptible to 
enzymatic dephosphorylation and deactivation (Mertens et al., 2006; Wenta et al., 2008; 
Zhong et al., 2005). Nonetheless, the exact details of these conformational shifts are still a 





Once exported to the cytosol, STATs can enter new cycles of re-activation, nuclear import, 
inactivation and nuclear export. Apart from canonical tyrosine-phosphorylation, STAT-driven 
transcription is also regulated by a number of posttranslational modifications, including serine 
phosphorylation and sumoylation (Droescher et al., 2011; Zhu et al., 1997). Another critical 
aspect of the JAK-STAT signalling pathway is its short-lived nature, generally confined to 
less than a few hours. This decline in the cascade is achieved through the activation of 
opposing regulatory proteins, namely phosphatases and suppressors of cytokine signalling 
(SOCS) (Adams et al., 1998), along with less well studied regulators such as protein inhibitor 
of activated STATs (PIAS) (Shuai, 2006), N-myc and STAT interactor (NMI) (Bao and 
Zervos, 1996), and PDZ and LIM domain-containing protein (SLIM) (Tanaka et al., 2005). 
Other phosphatases that regulate the JAK-STAT signalling involve: protein tyrosine 
phosphatase non-receptor type 1 (PTP1B), protein tyrosine phosphatase non-receptor type 2 
(TC-PTP), protein tyrosine phosphatase non-receptor type 6 (SHP-1), protein tyrosine 
phosphatase non-receptor type 11 (SHP-2), and protein tyrosine phosphatase non-receptor 
Type 13 (PTP-BL). Some of these regulators appear to target receptors and their associated 
JAKs, while others target the STATs directly and their nuclear export (Aman et al., 1997; 
Böhmer and Friedrich, 2014). 
1.1.3 STAT1  
STAT1 is a crucial activator of numerous immune effector functions and regulates the 
expression of genes that are involved in chemokine and cytokine signalling, antigen-
presentation, phagocytosis, anti-microbial, and anti-viral immunity. Therefore, expectedly 
humans carrying variants of STAT1 in the form of nonsense or missense mutations present 
clinically with a higher predisposition to bacterial and viral infections (Boisson-Dupuis et al., 
2012; Casanova et al., 2012). The identification of STAT1 was based on screening of human 
complementary DNA (cDNA) libraries, that were generated from HeLa cells treated with 
IFN- and IFN-α for 45 min and 16 hours, respectively. In particular, molecular cloning and 
sequence analysis of the cDNA eventually led to the characterization of the two forms p91 
and p84, termed as STAT1α and STAT1β, which are the products of alternative splicing of 
the same gene. Following nuclear import, STAT1 dimers that are not bound to DNA have a 
conformational change resulting in the exposure of a critical phosphotyrosine residue at 
position 701 (Staab et al., 2013). This conformational shift renders STAT1 susceptible to the 
removal of the phosphate group by T-cell protein tyrosine phosphatase (TC-45), which makes 





of STAT1 from DNA not only hampers the constant search for GAS (gamma-activated 
sequence) sites, but also impedes with the rate of nucleocytoplasmic shuttling and the 
transcriptional activity of STAT1 (Yang et al., 2002). Notably, unphosphorylated STAT1 also 
functions as a transcription factor. However, it is quickly substituted by activated STAT1 
dimers following IFN-γ stimulation (Yao et al., 2017). Hence, unphosphorylated STAT1 stays 
for several days in the cell, leading to enhanced signal transduction following re-exposure to 
low doses of interferon (Cheon and Stark, 2009). Additionally, experimental data suggested 
the existence of unphosphorylated homodimers, STAT1:STAT2 and STAT1:STAT3 
heterodimers before cytokine stimulus (Ho et al., 2016). 
1.1.4 STAT3   
In response to inflammation, binding of acute-phase response factor (APRF) to IL-6-
responsive elements in the DNA of target genes is known to activate the transcription of 
acute-phase proteins (APPs) (Gabay et al., 1999; Wegenka et al., 1993). Analysis of APRF 
revealed a mouse cDNA encoding the 770 amino acid-long homodimers of STAT3. In 
addition, Northern blot detected a single mRNA transcript (4.8 kb) in both mouse and human, 
corresponding to a protein product of 88 kDa. Stimulation of mouse liver cells for 3 hours 
with IL-6 has shown a 5-fold induction of STAT3 mRNA levels (Akira et al., 1994; Zhong et 
al., 1994). Expression of STAT3 transcripts has been found to be ubiquitous in all tissues 
examined. Previous research demonstrated that STAT3 can transduce signals from the IL-6 
and IL-10 families, as well as granulocyte-colony stimulating factor (G-CSF), leptin, IL-21, 
IL-27, and potentially IFN-Is (Akira et al., 1997). Moreover, in vitro studies have recently 
shown that different growth factors and oncogenes are inducing the activation of STAT3, 
which is associated with the expression of anti-apoptotic/pro-survival genes (Yeh et al., 
2009). Deletion of the Stat3 gene in mice resulted in an early lethal embryonic phenotype at 
embryonic day 6.5–7.5 (Takeda et al., 1997), while tissue specific Stat3 deletions 
demonstrated an inflammatory phenotype with decreased transformative capacity in cancer 
cells and tumor regression in animal models (Yu et al., 2009). Moreover, overexpression of 
the active Stat3 allele, using dominant negative inhibitors and RNA silencing, was associated 
with increased transformation capacity (Bromberg et al., 1998; Gough et al., 2009; Vultur et 
al., 2005). 
1.1.5 Type I and II interferon signalling  
The JAK-STAT1 pathway is activated by binding of type I and II interferons to their cognate 





Janus-activated kinases (JAKs) bound to these receptors (Darnell et al., 1994; Levy and 
Darnell, 2002). The mammalian family of JAKs consists of four ubiquitously expressed 
members: JAK1, JAK2, JAK3, and TYK2, but the expression of JAK3 is primarily limited to 
the hematopoietic cells. In type I interferon signalling, binding of several ligands induces the 
dimerization of type I interferon receptor subunits and the phosphorylation of their associated 
JAKs on specific tyrosine residues. This is followed by the phosphorylation of other tyrosine-
residues on the cytoplasmic receptor domains, creating docking sites for latent cytoplasmic 
STAT molecules, that bind through their Src-homology-2 (SH2) domain. Then, the STATs 
become phosphorylated by the JAKs on a conserved tyrosine residue near their C-terminus. 
Upon phosphorylation, the dissociation of STAT molecules from the receptor complex 
ensues, followed by dimerization via reciprocal phosphotyrosine (pY)-SH2 domain 
interactions. A complex which comprises STAT1, STAT2, and IRF9, called interferon-
stimulated gene factor 3 (ISGF3), is subsequently formed. The ISGF3 complex binds DNA on 
interferon-sensitive response element (ISRE) sequences (5´-AGTTTCN2TTTC-´3), to induce 
gene transcription of target genes. However, in type II interferon signalling, interferon- 
receptor subunits (IFNGR1 and IFNGR2) associate with JAK1 and JAK2, which 
phosphorylate exclusively STAT1. Two STAT1 monomers form a dimeric complex called 
gamma-activation factor (GAF), that after translocation to the nucleus and binds GAS sites 
(5 -́TTCN3GAA-´3) to activate gene transcription of IFN-γ-driven target genes. Thus, type I 
and II interferons translate extracellular signals and mediate differential transcriptional 
responses (Figure 2) (Lee and Ashkar, 2018). In addition, STATs nuclear translocation is 
regulated through two pathways, which are the importin α-5 dependent pathway and the Ran 








Figure 2: Differential regulation of type I and II interferons signalling pathways. IFN-α (type I 
IFN) leads to the formation of STAT1-STAT2 heterodimers, which also require IRF9 (interferon-
regulatory factor 9). This heterotrimeric complex known as ISGF3 (interferon- stimulated gene factor 
3) drives transcription at so-called ISREs (IFN-stimulated response elements) sites. IFN-γ (type II 
IFN) results in the formation of STAT1-STAT1 homodimers that are known as GAF, which binds to 
other DNA sequence, termed GAS sites, to drive transcription. 
 
1.1.6 STAT1-cooperative DNA binding 
It has been shown that phage lambda will enter a lytic or a lysogenic cycle by performing a 
swift switch utilizing cooperative DNA binding (Murray and Gann, 2007). Similarly, STAT 
dimers polymerize on tandem GAS and ISRE sites through N-terminal domain mediated 
interactions (Xu et al., 1996). Begitt and colleagues studied the role of cooperative DNA 
binding in type I and type II interferon signalling. The foundation of their work was the 
generation of a mutant mouse line (STAT1-F77A), which is defective in polymerizing 
additional STAT dimers on the DNA, as a result of a single amino acid substitution, namely 
alanine for phenylalanine at position 77 in the N-terminus domain. Infection experiments 
using this knock-in mouse line emphasized the physiological significance of STAT1 
tetramerisation in immunity. Although STAT1-F77A mice expressed similar levels of STAT1 
and responded similarly to vesicular stomatitis virus (VSV) infection, as compared to wild-
type littermates, they had a severe defect in antibacterial immunity, exhibiting a higher 





fibroblasts have shown an impaired induction of IFN-γ-regulated genes as compared to IFN-
α-regulated genes. Furthermore, using chromatin immunoprecipitation and electrophoretic 
mobility shift assays, STAT1-F77A recruitment to GAS sites was impeded upon IFN-γ 
stimulation as compared to wild-type cells, but not upon stimulation with IFN-α (Begitt et al., 
2014).  
1.1.7 Antagonistic activities of STAT1 and STAT3  
Phosphorylation of STAT proteins by JAKs is essential for facilitating STAT homo- and 
hetero-dimerization in a parallel dimer conformation. Upon binding of STATs to the 
receptors, phosphorylation of tyrosine residue 701 in STAT1 and tyrosine residue 705 in 
STAT3 occurs, followed by STATs dimerization and nuclear translocation to activate 
responsive genes. Accordingly, tyrosine-phosphorylated STAT1 can form dimers with 
STAT3 and with STAT2, and the balance between STAT1:STAT3 heterodimers and their 
STAT3 homodimers will define the transcriptional activity in a cell. Different group of 
cytokines have been shown to activate distinct STAT proteins. This differential potency of 
activation for certain cytokines is best exemplified by IFN-γ, a potent activator of STAT1, 
and STAT3 mediating signalling from interleukin-6 (IL-6) family members, in particular IL-
6, leukemia inhibitory factor (LIF) and cardiotrophin-1 (CT-1). Remarkably, STAT1 and 
STAT3 can substitute for each other absence following IFN-γ and IL-6 stimulation, this is 
characterized by GAS-dependent gene activation in STAT1-null cells, and enhanced 
activation of STAT1 in STAT3-null cells resulting in IFN-γ-like response (Costa-Pereira et 
al., 2002). Every STAT protein has a modular structure comprised of distinct domains. 
STAT1 and STAT3 display certain homology within the coiled-coiled domain, the DNA-
binding domain, the linker domain, the Src-homology (SH2) domain and the carboxy-terminal 
transactivation domain (TD). To the contrary, the amino-terminal domain is dramatically less 
conserved between STAT1 and STAT3, signifying this region as a mediator of cellular 
responses that are unique to distinctive STAT proteins. Even though STAT1 and STAT3 
share very comparable conserved structure, both have potential antagonistic effects of their 
gene products, which regulate processes such as cellular proliferation and apoptosis. For 
example, several studies have established that STAT1 plays an important role as a tumor 
suppressor promoting apoptosis in multiple cell types, however, STAT3 exhibits anti-
apoptotic activities. Additionally, while STAT3 promotes proliferation and transformation in 






Table 1: Antagonistic activities of STAT1 and STAT3  
 
1.2 The JAK/STAT signalling pathway in cardiovascular diseases 
Several animal models have been developed to investigate the role of various signalling 
pathways in cardiovascular function under normal or pathologically conditions, including the 
JAK/STAT signalling pathway, which is a key regulator of several cardiovascular 
pathologies. Studies have been performed on its function in atherosclerosis, hypertension, 
myocardial infarction, hypertrophy, myocarditis, and ischemia-reperfusion-induced cardiac 
injury (El-Adawi et al., 2003; Mascareno et al., 2001; Ortiz-Muñoz et al., 2009; Satou and 
Gonzalez-Villalobos, 2012; Zhang et al., 2013). In the myocardium, STATs regulate the 
expression of inflammation- and extracellular matrix-related genes as well as genes regulating 
apoptosis, angiogenesis and proliferation (Figure 3). 
 
 
Figure 3: STAT1 and STAT3 regulate transcriptional processes in the ischemic heart. The 
balance between the activation state of both members of the STAT protein family in the 
















1.2.1 Myocardial infarction and leukocytes responses  
Myocardial infarction (MI) triggers a cascade of events which recruit different types of 
immune cells such as neutrophils, macrophages, lymphoid cells, and mast cells to orchestrate 
several inflammatory responses. Following a cardiac insult, leukocytes move out of the 
circulation towards the site of injury, guided by a gradient of chemoattractant peptides, known 
as chemokines (Altara et al., 2016; Frangogiannis, 2014; Gomez et al., 2018; Meng et al., 
2016; Nahrendorf and Swirski, 2013; Pinto et al., 2012). Recruited monocytes and neutrophils 
are initially mobilized from their original niche in the bone marrow to the spleen, generating 
myeloid cells that take part in multiple repair processes (Lambert et al., 2008; Nahrendorf et 
al., 2007). Heart-infiltrating immune cells perform a complex role clearing debris and 
stabilizing the heart wall, through a tuned balance between residents and 
recruited/differentiated hematopoietic progenitors (Heidt et al., 2014; Massa et al., 2005; 
Nahrendorf and Swirski, 2016). Hence, trafficking of immune cells shapes the outcome 
following myocardial infarction by profoundly influencing cardiac repair, fibrosis, 
regeneration and scar formation, and exerting either pro-inflammatory or anti-inflammatory 
actions (Forte et al., 2018; Ruparelia et al., 2015). Activated chemokines signal through G-
protein-coupled receptors, which are expressed on various immune cells. Dissociation of the 
- and --subunits of G-proteins leads to downstream signalling cascades which ultimately 
result in changes in cell polarity and motility through small GTPases (Zweemer et al., 2014). 
For example, highly coordinated migration and velocity of neutrophils towards sites of injury 
are established and maintained by cell adhesion molecules (CAMs). Notably, CAMs underpin 
a crucial cross-talk between innate and adaptive immune cells. They can either anchor the cell 
to the substratum or transduce signals between adjacent cells to reshape their migratory 
responses and dynamically remodel the organization of their actin cytoskeleton.  
The migration of neutrophils into extravascular tissue can be viewed as a series of interactions 
which is mediated by (1) the integrin family, (2) the immunoglobulin superfamily, (3) 
selectins, and (4) cadherins. CAMs can also be classified according to the role they play to (1) 
recognize antigens, (2) adhere to each other and to the extracellular matrix, and (3) carry co-
stimulation signal (Cavallaro and Dejana, 2011). Additionally, activated chemokine receptors 
stimulate a rapid elevation of diacylglycerol and cytosolic calcium levels to induce effector 
functions and coordinate microvascular remodeling, including nitric oxide production and 
release of reactive oxygen species (ROS) (Cavalera and Frangogiannis, 2014; Saparov et al., 
2017). The ensuing removal of dead cells sustains a local environment that supports 





which can be stimulated by collagen, von Willebrand factor (VWF), thromboxane A2 
(TXA2), adenosine diphosphate (ADP), and thrombin. The proceeding thrombus formation 
within the ventricle increases the myocardium stiffness (Dutta et al., 2012). Furthermore, 
myocardial ischemia reprograms catabolic and anabolic pathways in the heart to adjust for 
new requirements of energy acquisition and substrate utilization, and mediate repair 
processes, cell survival, and growth (Meyer and Voigt, 2017; Wende et al., 2017). Nearly a 
century ago, Otto Warburg found that cancer cells favor the metabolization of glucose via 
aerobic glycolysis. Similarly, deregulated metabolism with increased glycolysis has emerged 
as a significant hallmark of ischemic injury in the heart (Chen et al., 2018). The goal in near 
future would be to enhance our understanding of the metabolism mediated through the 
JAK/STAT signalling and propose a rational basis to reprogram metabolic pathways for an 
improved cardiac repair and regeneration (Doenst et al., 2013).  
1.2.2 Regulation of leucocyte transendothelial migration by the JAK/STAT pathway 
Cell migration is an intricate, synchronized process in which numerous parts of the cell are 
involved, including surface receptors, intracellular signalling proteins, and the cytoskeleton. 
Cumulating evidence has highlighted the role of inflammatory cytokines and transcription 
factors as crucial mediators of cell migration and polarization (Dustin and Chan, 2000; Nieto 
et al., 1997; Randolph, 2001). One of the best studied examples in cellular polarity is the 
epithelial-to-mesenchymal transition, in which cells lose epithelial polarity and attachment to 
adjacent cells (Lamouille et al., 2014). The inverse happens when migrating cells arrive at 
their target location, build an epithelium and/or integrate into a previous epithelial tissue 
(Muller, 2015). Examples of such transitions taking place are demonstrated by neural crest 
development in vertebrates (Bronner and LeDouarin, 2012). Similarly, heart regeneration 
depends on overlooked temporal and spatial roles for macrophages and neutrophils, where 
they mediate extracellular matrix regulation. Consequently, improper migration and 
polarization can potentially affect repair processes and thus contribute to the development of 
heart failure. STAT1 was found to be essential for IL-6 expression and the increased adhesion 
and migration of monocytes across the blood-brain barrier, using different in-vitro models in 
human immunodeficiency virus 1 (HIV-1) infection (Yang et al., 2009). Another study has 
shown that depletion of STAT1 in a fibroblast cell line resulted in a reduction of cell 
migration (Xie et al., 2001). Whereas, IFN- treatment arrested monocyte chemotaxis by 
modulating the organization of the cytoskeleton via RAC/CDC42 pathways (Hu et al., 2008). 





activity in murine embryonic fibroblasts, which mediated a random type of migration through 
decreasing directional persistence and the assembly of actin stress fibers (Marcella et al., 
2005; Teng et al., 2009). These findings suggest a major role of STAT1 and STAT3 in 
chemokine-induced leucocyte transendothelial migration. 
1.3 Original hypotheses and aims of this thesis  
There is accumulating evidence defining a critical role for cytokines in post-myocardial 
infarction remodeling. While there is ample evidence indicating a pivotal cardioprotective 
role of STAT3 in acute and chronic stress in the heart (Zouein et al., 2015), only a small 
proportion of the studies carried out have investigated the functional role of STAT1. It is 
proposed that STAT1 deficiency in the heart has a cardioprotective role by enhancing 
autophagy (McCormick et al., 2012). Accordingly in this thesis, the pleiotropy of STAT1 
action and the nature of its transcriptional program in the failing myocardium was studied, 
with its subsequent impact on cardiac function using genome-wide profiling of the cardiac 
transcriptome in infarcted areas of wild-type and STAT1 tetramerisation-deficient mice 
(STAT1-F77A).  
This project investigates the biological roles of STAT1-cooperative DNA binding in a murine 
model of myocardial infarction. In order to test our hypothesis, the following aims were 
established to:  
1) understand the role of STAT1 as a transcription factor and the function of its 
downstream effector genes responding to myocardial infarction, as well as their 
potential cross talk in normal and dysfunctional signaling,  
2) investigate the potential role of the antiviral program “type-II interferon response” 
in pathophysiological remodeling, by identifying signalling pathways that are 
differentially regulated between wild-type and transgenic STAT1-F77A animals 
following injury of the myocardium, and   
3) perform proof-of-concept experiments to study the functional role of STAT1 and 
STAT3 in mediating transendothelial migration in a neutrophil-like cell line, by 
generating STAT1- and STAT3-knockdown HL-60 cells. 




2. Materials and Methods 
2.1 Materials  
2.1.1 Chemicals and reagents 
Table 2: List of chemicals and reagents  
Name Company 
3,3’-Diaminobenzidine (DAB) Sigma-Aldrich, Taufkirchen, Germany 
4-(2-Hydroxyethyl)-1-
piperazineethanesulphonic acid (HEPES, 
Pufferan ≥99.5%, p. a.)  
Carl Roth, Karlsruhe, Germany 
Agarose Carl Roth 
Ammonium persulphate (APS) Carl Roth 
Ampicillin Sigma-Aldrich 
Bovine serum albumin (BSA) Fraction V Carl Roth 
Bromophenol blue Fisher Bioreagents, Pittsburgh, USA 
Chloroform Sigma-Aldrich 
Complete mini proteinase inhibitor cocktail Roche, Rotkreuz, Switzerland 
Deoxy-adenosine triphosphate (dATP) [33P]-
labelled 
Hartmann Analytic, Braunschweig, 
Germany 
Deoxynucleotide triphosphates (dNTP) Carl Roth 
Dimethyl sulphoxide (DMSO) Applichem, Darmstadt, Germany 
Dithiothreitol (DTT) Applichem 
Entellan Merck Millipore, Darmstadt, Germany 
Eosin Y Merck Millipore 
Ethanol (99.8%) Carl Roth 
Ethidium bromide solution (0.625 g/ml) VWR Life Science, Erlangen, Germany 
Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N’,N’-tetraacetic acid (EGTA) 
Carl Roth 
Ethylenediamine-tetraacetic acid (EDTA) Sigma-Aldrich 
Fetal bovine serum (FBS) Biochrom, Berlin, Germany 
Fluoromount G Southern Biotech, Birmingham, USA 
Formaldehyde solution (37%) Carl Roth 
L-Glutamine Thermo Fisher Scientific, Langenselbold, 





Glycerol, ROTIPURAN ≥99.5%, p. a. Carl Roth 
Glycine Carl Roth 
HEPES, cell culture grade Carl Roth 
Hydrogen peroxide solution (30%) Carl Roth 
IGEPAL CA-630 Sigma-Aldrich 
Isopropanol Carl Roth 
Kanamycin Sigma-Aldrich 
Lithium chloride Carl Roth 
Magnesium chloride Sigma-Aldrich 
Mayer’s haemalum Merck Millipore 
Mercaptoethanol Sigma-Aldrich 
Methanol Merck Millipore 
Methylene blue with (3%) acetic acid Stemcell, Cologne, Germany 
Pefabloc Roche 
Penicillin/streptomycin Biochrom 
Phenol/chloroform/isoamylalcohol (25:24:1) Carl Roth 
Phosphate-buffered saline (PBS) Life Technologies, Darmstadt, Germany 







Potassium chloride  Merck Millipore 
Puromycin Sigma-Aldrich 
Radioimmunoprecipitation assay buffer (RIPA) Merck Millipore 
Rotiphorese gel 30 (acrylamid/bisacrylamid 
(37.5:1)-solution) 
Carl Roth 
Rotiphorese gel 40 (acrylamid/bisacrylamid 
(29:1)-solution) 
Carl Roth 
Roti-plast paraffin Carl Roth 
Sodium acetate Carl Roth 
Sodium azide Thermo Fisher Scientific 
Sodium bicarbonate Carl Roth 




Sodium chloride Carl Roth 
Sodium chloride solution (0.9%) B. Braun, Melsungen, Germany 
Sodium citrate  Carl Roth 
Sodium deoxycholate Applichem 
Sodium dodecyl sulphate (SDS) Carl Roth 
Sodium orthovanadate Acros Organics, Geel, Belgium 
Sodium pyruvate Thermo Fisher Scientific 
Sulfuric acid Carl Roth 
Tetramethylethylenediamine (TEMED) Carl Roth 
Tris-base Carl Roth 
Tris-HCl Carl Roth 
Triton X-100 Carl Roth 
TRIzol reagent Thermo Fisher Scientific 
Tween-20 Carl Roth 
Xylene Merck Millipore 
 
Table 3: List of drugs 
Name  Company 
Cepetor (medetomidine, 1 mg/ml)  Cp-pharma, Burgdorf, Germany 
Fentanyl (0.05 mg/ml)  Rotexmedica, Trittau, Germany 
Flumazenil(0.5mg/ml)  Inresa Arzneimittel, Freiburg, Germany 
Isoflurane Abbvie, Wiesbaden, Germany 
Ketamine Medistar, Ascheberg, Germany  
Midazolam (5 mg/ml) Rotexmedica 
Metamizol (500 mg/ml) Zentiva Pharma, Frankfurt am Main, Germany  
Atipamezole hydrochloride (5 mg/ml) Cp-pharma  
Buprenorphine hydrochloride  Reckitt Benckiser, Slough, UK 
Xylazine hydrochloride Ecuphar, Greifswald, Germany  
  




2.1.2 Recombinant proteins and enzymes 
Table 4: List of recombinant proteins and enzymes 
Name Company 
IFN-α, human, recombinant from E. coli  Biomol, Hamburg, Germany 
IFN-γ, human, recombinant from E. coli Biomol 
IL-6, human recombinant  Biomol 
InnuTaq DNA polymerase Analytic Jena 
InnuTaq HOT-A DNA polymerase Analytic Jena 
Proteinase K Carl Roth 
Taq polymerase Ares Bioscience, Köln, Germany 
Trypsin Sigma-Aldrich  
Tsp509I Thermo Fisher Scientific 
 
2.1.3 Water 
Table 5: List of water 
Double-distilled H2O  PURELAB Plus purification system, Elga 
Labwater, Celle, Germany 
Molecular biology grade water  
DNase-, RNase- and proteinase-free water 
5 Prime, Heidelberg, Germany 
 
2.1.4 Kits 
Table 6: List of kits 
Name Company 
ABsolute Blue QPCR SYBR Green Mix Thermo Fisher Scientific 
dsDNA 905 Reagent Kit Advanced Analytical Technologies, 
Heidelberg, Germany 
PeqGold total RNA Kit VWR Life Science 
QuantiFluor dsDNA System Promega 
Thermo Scientific Verso cDNA Synthesis Kit Thermo Fisher Scientific 
TruSeq stranded mRNA prep Kit Illumina, California, USA 
  




2.1.5 Culture media 
Table 7: List of media 
Name Company 
Dulbecco’s modified Eagle’s medium (DMEM) (Glucose 
4.5 g/l, 580 mg/l L-glutamine, 110 mg/l Na-pyruvate) 
Biochrom 
DMEM (Glucose 4.5 g/l, without L-glutamine, 110 mg/l 
Na-pyruvate) 
Biochrom 
RPMI (Roswell Park Memorial Institute medium) 1640 Lonza, Cologne, Germany 
Endothelial cell growth medium PromoCell, Heidelberg, 
Germany 
 
2.1.6 Cell lines and animals 
Table 8: List of cell lines 
Cell line Characteristics 
HL-60 Human suspension cell line derived from peripheral blood acute promyelocytic 
leukemia, exhibit phagocytic activity and responsiveness to chemotactic stimuli 
HUVEC Human umbilical vein endothelial cells are cells derived from the endothelium of 
veins from the umbilical cord 
 
Table 9: List of animals 
Animal model Description  
STAT1-F77A 
knock-in 
Mouse line carrying a point mutation resulting in a 
substitution of alanine in position 77 for phenylalanine 
on a C57BL6/N background (Charles Rivers, Sulzfeld, 
Germany) 




Mice were kept in individually ventilated cages in the University Medical Centre Animal 
Facility, Göttingen. Experiments performed were approved by the Lower Saxony State Office 
for Consumer Protection and Food Safety (Niedersächsisches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit, LAVES). 
  




2.1.7 shRNA lentiviral transduction particles 
Table 10: List of STAT MISSION shRNA lentiviral transduction particles 


























Table 11: List of oligonucleotide primers for genotyping  
Gene  Sequence  
Stat1-F77A  F: 5’-CGCGAATTGCTAATAAAACAA G-3’  
R: 5’-TGCTGCTGAGTCCAAATAAAG-3’  
Stat1-WT  F: 5’-GGCTGACCTTGGAACTTGTG-3’  
R: 5’-AAGAGTCAGCAGGGGTCTGA-3’ 
  




Table 12: List of oligonucleotide primers for quantitative PCR (qPCR) 
Gene  Sequence  
Bcl2l1 F: 5’-GCCTTTTTCTCCTTTGGCGG-3’ 
R: 5’-TCCACAAAAGTGTCCCAGCC-3’ 
Cd34 F: 5’-AGGCTGATGCTGGTGCTAG-3’ 
R: 5’-AGTCTTTCGGGAATAGCTCTG-3’ 
Cox7a F: 5’-AAAACCGTGTGGCAGAGAAG-3’ 
R: 5’-CAGCGTCATGGTCAGTCTGT-3’ 
Csf3r F: 5’-TGAACTACACCCAGGCCTTC-3’ 
R: 5’-GTGCATGAGGCAGGATAGGT-3’ 
Cxcl2 F: 5’-GCAAGGCTAACTGACCTGGA-3’ 
R: 5’-AGGCACATCAGGTACGATCC-3’ 
Cxcl9 F: 5’-GGAGTTCGAGGAACCCTAGT-3’ 
R: 5’-AGGCAGGTTTGATCTCCGTT-3’ 
Gbp2b F: 5’-AAGGGCATCTGGATGTGGTG-3’ 
R: 5’-TCTGGTTGTCACCCTTCTGC-3’ 
Hprt F: 5’-AGTCCCAGCGTCGTGATTAG-3’ 
R: 5’-TGATGGCCTCCCATCTCCTT-3’ 
Irf1 F: 5’-ACCCTGGCTAGAGATGCAGA-3’ 
R: 5’-TGCTTTGTATCGGCCTGTGT-3’ 
Kras F: 5’-CAAGAGCGCCTTGACGATACA-3’ 
R: 5’-CCAAGAGACAGGTTTCTCCATC-3’ 
Nnmt F: 5’-GAAGGCAACAGAATGAAGGGAC-3’ 
R: 5’-TTCCTGAGGGCAGTGCGATA-3’ 
Rb1 F: 5’-ACTCCGTTTTCATGCAGAGACTAA-3’ 
R: 5’-GAGGAATGTGAGGTATTGGTGACA-3’ 
Sca1 F: 5’-AGGAGGCAGCAGTTATTGTGG-3’ 
R: 5’-CGTTGACCTTAGTACCCAGGA-3’ 
Stat1 F: 5’-CCGTTTTCATGACCTCCTGT-3’ 
R: 5’-TGAATATTCCCCGACTGAGC-3’ 
Thy1 F: 5’-TCCAGAATCCAAGTCGGAAC-3’ 
R: 5’-GTTATTCTCATGGCGGCAGT-3’ 
Primers were purchased from Sigma with a grade of purification as desalted. NCBI-BLAST 
tool was used for primer design.  





Table 13: List of primary antibodies 
Name Company Cat-No. 
Ezrin Cell Signaling Technology, Frankfurt am Main, 
Germany 
3145  
Moesin (C-15) Santa Cruz Biotechnology, Heidelberg, Germany sc-6410 
STAT1(D1K9Y) Cell Signaling Technology  14994 
pSTAT1 (Tyr701)(58D6) Cell Signaling Technology  9167 
STAT3 (D1B2J) Cell Signaling Technology  30835 
STAT3 (H-190) Santa Cruz Biotechnology sc-7179  
pSTAT3 (Tyr705) (D3A7) Cell Signaling Technology  9145 
GAPDH (14C10) Cell Signaling Technology 2118 
-actin (8H10D10) Cell Signaling Technology  3700 
 
Table 14: List of secondary antibodies 
Name Company Cat-No. 
Donkey anti-rabbit secondary antibody 
IRDye 800CW IgG (H + L) 
LI-COR Biosciences 926-32213  
 
Donkey anti-mouse secondary antibody 
IRDye 800CW IgG (H + L) 
LI-COR Biosciences 926-32212 
Donkey anti-Goat secondary antibody 
IRDye 680RD IgG (H + L) 
LI-COR Biosciences 925-68074 
Biotinylated anti-rabbit IgG (H+L)  
derived from goat 
Vector Laboratories, 




2.1.10 Equipments  
Table 15: List of equipment 
Name Company 
5075 ELV autoclave  Tuttnauer Europe B.V., Breda, Netherlands 
Bandelin Sonopuls Bandelin electronic, Berlin, Germany 
Biological safety cabinet class II Thermo Fisher Scientific 
BioPhotometer plus Eppendorf, Hamburg, Germany 




Centrifuge 5804 R Eppendorf 
Digital video camera C10600 ORCA-R2 Hamamatsu, Hamamatsu, Japan 
Fragment analyzer  Advanced Analytical Technologies 
Freezing container Nalgene, Rochester, USA 
Illumina HiSeq 4000  Illumina 
Incubator B 5061 EC-CO2 Heraeus, Hanau, Germany 
Microscope incubator Solent Scientific 
Microcentrifuge 5415 R Eppendorf 
Microscope, BX51 Olympus, Tokyo, Japan 
Microscope, fluorescent, Axiovert 200M Zeiss, Oberkochen, Germany 
Microscope, inverted, Axiovert 40 CFL Zeiss 
Microtome SM 2000 R Leica Microsystems, Wetzlar, Germany 
Mini vent type 845 FMI GmbH, Seeheim-Jungenheim, Germany 
Multifuge 1S-R Heraeus 
Neubauer-modified counting chamber Paul Marienfeld, Königshofen, Germany 
Odyssey CLx imaging system 
LI-COR Biosciences, Bad Homburg vor der 
Höhe, Germany 
Olympus IX81 time-lapse inverted 
fluorescence microscope  
Olympus 
Orbital shaker VWR Life Science 
Pipettes, type research (P1000, P200, P100, 
P10, P2.5) 
Eppendorf 
Power supply unit Biometra, Göttingen, Germany 
QuantiFluor dsDNA system  Promega, Mannheim, Germany 
Real-time cycler mastercycler ep gradient  Eppendorf 
Rocker duomax 1030 Heidolph, Schwabach, Germany 
SDS-PAGE gel running system Biometra 
Semi-dry blotting cell Peqlab Biotechnologie, Erlangen, Germany 
Sonicator UW 2070 Bandelin electronic 
Speedmill tissue homogenizer Analytic Jena, Jena, Germany 
Surgical forceps Fine Science Tools, Heidelberg, Germany 
Surgical scissors Fine Science Tools 




Thermo shaker TS1 Biometra 
Tissue dehydration system TP1028 Leica Microsystems 
UVsolo TS imaging system Analytic Jena 
Vevo 2100 System Visualsonics, Toronto, Canada 
Waterbath GFL Schuett-biotec, Göttingen, Germany 
XCell II blot module Thermo Fisher Scientific 
XCell SureLock mini-cell electrophoresis 
system 
Thermo Fisher Scientific 
 
2.1.11 Disposables 
Table 16: List of disposables 
Name Company 
Cell culture flasks, T75 Sarstedt, Nümbrecht, Germany 
Cell culture plates, 6-well, 24-well, 96-well Sarstedt 
Cell scraper 25 cm Sarstedt 
Cryovials Nunc, Roskilde, Denmark 
Ethilon 9-0 BV-4 5.0 mm 3/8c EH7448G 
surgical silk 
Ethicon, Norderstedt, Germany 
Falcon tubes, 15 ml, 50 ml Sarstedt 
Filter (0.22 µm) Carl Roth 
Glass cover slip Thermo Fisher Scientific 
Glass microscope slide Thermo Fisher Scientific 
Injection needles B. Braun, Melsungen, Germany 
Insulin syringe, 29 G B. Braun 
Microreaction tube, 0.2 ml, 1.5 ml, 2 ml Eppendorf 
Minisart NY 25 syringe filter  Sartorius, Göttingen, Germany 
Nitrocellulose membrane GE Healthcare, Braunschweig, Germany 
PCR-plate (96 well) Nunc 
Petri dishes, 10 cm Corning, New York, USA 
Pipette tips (P1000, P100, P10) Sarstedt 
Prolene 6-0 C-1 13 mm 3/8c 8889H surgical 
silk 
Ethicon 




Polyvinylidene fluoride membrane 
Immobilon-P (PVDF) 
Merck Millipore 
Serological pipettes, 5 ml, 10 ml Sarstedt 
Syringe, 20 ml, 10 ml Becton Dickinson, Heidelberg, Germany 
Tissue culture dish 20 cm  Nunc 
Tissue culture plates, 96 well, 24 well, 6 well Nunc 
 
2.1.12 Software 
Table 17: List of software 
Name Description Distributor 
BaseCaller Base calling for sequence files Illumina 
bcl2fastq  
(version 2.17.1.14) 
Formats conversion software Illumina 
biomaRt 
(version 2.32.1) 
Gene annotation to database 
mining 
Bioconductor R package 
BLAST Basic local alignment search 
tool   
National Human Genome Research 
Institute, Bethesda, USA 
CorelDraw Vector graphics editor  Corel, Ottawa, Canada 
DESeq2 package 
(version 1.14.1.) 
Differential gene expression 
analysis based on the negative 
binomial distribution 
Bioconductor R package 
FastQC 
(version 0.11.7)  
Quality control check on 
sequences 
Babraham Institute, Cambridge, UK 
featureCounts 
(version 1.4.5-p1) 
Assigning sequence reads to 
genomic features  
Bioconductor R package 
FlowJo Flow cytometry data analysis FlowJo LLC, Ashland, USA 
GraphPad Prism Analysis and graphing solution  GraphPad, San Diego, USA 
IBM SPSS  Statistical software, Version 24 IBM, Kassel, Germany 
ImageJ Image processing software NIH, Bethesda, USA 
ImageStudio Lite Image processing software LI-COR Biosciences 
Inkscape 2 Vector graphics editor  Inkscape 
Realplex ep qPCR running and data analysis 
software 
Eppendorf 




RStudio Open-source integrated 
development environment for 
statistical computing  
RStudio Inc. Boston, USA 
SigmaPlot Scientific data analysis and 
graphing  
Systat Software, Erkrath, Germany 
Snapgene DNA cloning and PCR tools GSL Biotech, Chicago, USA 
STAR aligner  
(version 2.5.2a) 
NGS read aligner  National Human Genome Research 
Institute 
Vevo 2100  Ultrasound analysis software 
for image data 
FUJIFILM, Tokyo, Japan 
Volocity Software 3D analysis of fluorescence 
images 
PerkinElmer, Baesweiler, USA 
Windows Office Spreadsheet for calculation and 
graphing tools 
Microsoft, Washington, USA 
 
 





2.2.1 Cell culture 
2.2.1.1 Thawing frozen cells  
To unfreeze cells, a cryovial containing 2 × 106
 
cells was thawed by gentle agitation in a 
water bath set at 37°C. When most of the ice started to melt, the vial was removed from the 
water bath and added immediately to 10 ml of pre-warmed culture medium. The cell 
suspension was centrifuged at 65 × g for 6 min at room temperature. Supernatant was 
carefully aspirated, leaving the pellet undisturbed to be resuspended in 10 ml of pre-warmed 
culture medium and cultured in a T75 flask. MHEC5-T cells were cultured in DMEM, 
supplemented with 10% FBS and 1% penicillin/streptomycin. HL-60 cells were cultured in 
RPMI 1640, supplemented with 10% FBS and 1% penicillin/streptomycin, in the additional 
presence of L-glutamine and 1 μg/ml puromycin. 
2.2.1.2 Harvesting of cells for cryopreservation 
Cells were harvested by trypsinization after washing with PBS for adherent cells, or by 
centrifugation for suspension cells. Adherent cells were incubated with trypsin for 2 min, and 
then centrifuged at 65 × g for 5 min. Cryopreservation medium was prepared by adding 
DMSO to FBS at a final concentration of 10% (v/v), which was placed on ice until ready to 
use. The cell pellet was resuspended in 1 ml of cold freezing medium at the recommended 
viable cell density (1.5 × 106 –10 × 106). The cryovials were stored at -80°C. 
2.2.1.3 Maintenance of cultured cells 
Cells were maintained at 37°C in 5% CO2 under a humidified atmosphere and passaged every 
2 to 3 days. MHEC5-T cells were washed with PBS and subsequently trypsinized for 2 min at 
37°C. Trypsinization was stopped by adding 5 ml of complete culture medium. An aliquot 
from this suspension was used to seed a new T75 flask with 1:10 dilution. HL-60 cells were 
counted and then subcultured at a density of 0.5 × 106 cells per ml. Cells were grown at 
densities no greater than 2.5×106 per ml. For protein and RNA analysis, MHEC5-T cells were 
seeded in a 6-well plate at a density of approximately 1.5 × 105 cells per cm2, and HL-60 cells 
were seeded in a 6-well plate at a density of 2 × 106 cells per ml. Absence of mycoplasma 
infection was routinely checked in the cell lines.  




2.2.1.4 Treatment of cultured cells with different stimuli 
MHEC5-T were treated with the respective stimulus (e.g. IFN-γ, IL-6) after removing the 
medium and replacing it with cytokine-containing medium at the indicated concentration. For 
stimulating HL-60 cells, without removing the media, the cytokine was added from an 
intermediate stock media to achieve the indicated concentration. For RNA extraction, cells 
were exposed 16 h prior to stimulation to a medium which had 0.5% FBS (low serum-culture 
medium). Stimuli concentrations were the following: human IFN-γ 50 ng/ml, murine IFNγ 5 
ng/ml, and murine IFN-α 5 ng/ml, human IL-6 10 ng/ml, and murine IL-6 10 ng/ml.   
2.2.1.5 Lentiviral transduction of HL-60 cells  
Expression of STAT1 and STAT3 genes were knockdown in HL-60 cells using MISSION 
TRC shRNA lentiviral transduction particles (SIGMA) with pLKO.1 plasmid, using standard 
puromycin selection method. At the first day, 100 μl of HL-60 cells were plated at a density 
of 1 × 106 cells per ml in a complete medium in 96-well plates prior to transduction. The 
lentiviral stock was slowly thawed on ice and then added to each well with a multiplicity of 
infection (MOI) of 5. At day 4, 100 μl of puromycin was added to the transfected cells with a 
concentration of 1 μg/ml. Cells were observed under the microscope for viability and 
passaged by adding fresh puromycin-supplemented media according to the cell density. Cells 
were transferred to a 6-well plate and subsequently cultured in a T25 and then a T75 flask, as 
they continued to proliferate.  
2.2.2 Protein Analysis 
2.2.2.1 Cell lysis and fractionation  
Cells grown on a 6-well plate were washed with PBS, then lysed on ice for 5 min with 50 μl 
of complete cytosolic protein lysis buffer (20 mM HEPES, 10 mM KCl, 1 mM EDTA, 100 
μM Na3VO4, 10% glycerol, 0.1% IGEPAL CA-630, supplemented with 1% Complete 
proteinase inhibitor cocktail, 3 mM DTT, 0.4 mM Pefabloc, pH 7.4). Adherent cells were 
harvested using a cell scraper and then transferred to a 1.5 ml tube. Cells were spun down for 
15 sec at 4°C and 16100 × g. The supernatant was transferred to a fresh tube and centrifuged 
again for 5 min at 4°C and 16100 × g. The resulting supernatant was collected as a cytosolic 
extract. The pellet from the first centrifugation was lysed with 50 μl of complete nucleic 
protein lysis buffer (20 mM HEPES, 420 mM KCl, 1 mM EDTA, 100 μM Na3VO4, 20% 
glycerol, supplemented with 1% complete proteinase inhibitor cocktail, 3 mM DTT, and 0.4 
mM Pefabloc, pH 7.4) and incubated for 30 min on ice, followed by centrifugation for 15 min 




at 4°C and 16100 × g. The supernatant was collected as a nucleic extract. The cytosolic and 
nucleic extracts were pooled and stored at -80°C for further use. In total, 14 μl of 6× Laemmli 
buffer (350 mM Tris-HCl, 8% SDS, 30% glycerol, 10% mercaptoethanol, 0.04% 
bromophenol blue, pH 7.4) were added to each protein extract. Samples were then boiled at 
95°C for 3 min and stored at -20°C for Western blotting analysis.  
2.2.2.2 Protein extraction of HL-60 cells 
HL-60 cells were harvested by centrifugation at 65 × g. Pellets were lysed in 300 μl of 2.5× 
protein loading buffer (200 mM Tris-HCl pH 6.8, 8% SDS (v/v), 20% glycerol (v/v), 0.4% 
bromophenol blue (w/v)). Protein extracts were sonicated for few pulses and subsequently 
incubated at 95°C for 5 minutes to complete protein denaturation. Finally, samples were 
stored at -20°C until further analysis. 
2.2.2.3 Western blotting analysis 
Protein samples were loaded into the wells of a two-phase 10% SDS-PAGE gel, along with 
the molecular weight marker. The stacking gel solution was made by adding 25% stacking gel 
buffer (500 mM Tris-HCl, 0.4% SDS, pH 6.8), 16% Rotiphorese Gel 30, 0.6% APS, and 
0.2% TEMED in double-distilled H2O. The separating gel solution was made by mixing 25% 
separating gel buffer (1.5 mM Tris-HCl, 0.2% SDS, pH 8.8), 33.1% Rotiphorese Gel 30, 
0.03% APS, and 0.16% TEMED in double-distilled H2O. SDS-PAGE running buffer (25 mM 
Tris-base, 192 mM glycine, 0.1% SDS, pH 8.6) was used to run the gels at 11 mA. A semi-
dry blotting system was used at 80 mA for 90 min with transfer buffer (25 mM Tris-base, 150 
mM glycine, 10% methanol, pH 8.0). A polyvinylidene difluoride (PVDF) membrane was 
activated with methanol for 1 min and rinsed with transfer buffer before preparing the stack. 
The membrane was subsequently blocked for 1 h at room temperature using blocking buffer, 
4% BSA in Tris-buffered saline (TBS: 137 mM NaCl, 10 mM Tris-HCl, pH 7.4) 
supplemented with 0.1% Tween-20 (TBS-T). The membrane was incubated with the 
appropriate dilutions of primary antibody in blocking buffer overnight at 4°C. The blot was 
washed five times for 5 min with TBS-T before being incubated with the diluted secondary 
antibody (prepared in blocking buffer) for 1 h at room temperature in the dark. The membrane 
was washed five times with TBS-T and once with TBS, 5 min each. For signal reading, the 
blot was scanned using the LI-COR Odyssey CLx imaging system. For reblotting, the 
membrane was washed three times for 15 min in TBS-T, then incubated overnight with a new 
primary antibody for next day development. When necessary, the blot was stripped with 
stripping buffer (62.5 mM Tris-HCl, 2% SDS, 0.7% mercaptoethanol, pH 6.8) at 60°C for 1 h. 




Afterward, it was thoroughly washed with tap water followed by four times TBS-T for 15 
min. The blot was blocked with blocking buffer for 1 h at room temperature and incubated 
overnight with a new primary antibody. The dilutions of used antibodies were as follows: 
anti-ezrin 1:1000, anti-GAPDH 1:5000, anti--actin 1:5000, anti-phosphotyrosine-STAT1 
1:1000, anti-phosphotyrosine-STAT3 1:1000, anti-STAT1 1:1000, and anti-STAT3 1:1000. 
The IRDye 800CW-conjugated donkey anti-rabbit secondary antibody used for detection was 
diluted 1:15000, and IRDye 800CW-conjugated donkey anti-mouse secondary antibody was 
diluted 1:15000.  
2.2.2.4 Electrophoretic mobility shift assay 
Native protein samples were incubated with radioactively labelled DNA probes in the 
presence of the non-specific competitor poly-dIdC. A native polyacrylamide gel was used to 
run the samples. The reaction mix contained 0.2 μl of the DNA probe, which was added to 1 
μl poly-dIdC (2 mg/ml), 1.3 μl DTT (100 mM), 3.5 μl H2O, and 2.5 μl 5× EMSA loading 
buffer (100 mM HEPES, 200 mM KCl, 5 mM MgCl2, 2.5 mM EDTA, 0.5 mM EGTA, 20% 
Ficoll). The reaction mix was incubated for the indicated time points with 4.5 μl of protein 
extracts. In supershift reactions, the STAT1 C-24 antibody was used, while the STAT3 H-190 
antibody was used as a negative control. The reactions were loaded onto an equilibrated non-
denaturing 4.8% TBE-polyacrylamide gel (12% Rotiphorese Gel 40, 2.4% TBE (89 mM Tris-
base, 89 mM boric acid, 2 mM EDTA), 2% APS, 0.1% TEMED) and run using 0.25× TBE at 
400 V. After the run, Whatman blotting paper was pressed against the gel and the gel was 
then vacuum-dried. The radioactive signal was recorded using a phospho-imager film and 
read by FLA-5100 scanner using TINA v 2.0 software. 
2.2.2.5 Radioactive labelling of EMSA probes 
Oligonucleotides were diluted at a concentration of 100 mmol/l in DNase-, RNase- and 
proteinase-free water and incubated at 95°C in a water bath. Mixtures were cooled overnight 
at room temperature for proper annealing and stored at -20°C. Five units of Klenow fragment 
from E. coli DNA polymerase I were mixed with 5 μl of 10 × Eco-Pol buffer, 0.1 ng annealed 
oligonucleotides, and 6 μl of [33P]-labelled ATP and incubated for 25 min at room 
temperature. Following that, an excess of non-radioactive dNTPs (6.5 mM of each dNTP) was 
added for 5 min. The reaction was stopped by the addition of 1 μl of 0.5 mM EDTA. Free 
nucleotides were removed by centrifugation at 700 × g for 3 min. 




2.2.3 DNA analysis 
2.2.3.1 DNA isolation from mouse tails 
Tail biopsy samples were lysed in 500 μl of tail extraction buffer (100 mM Tris, 5 mM 
EDTA, 200 mM NaCl, 0.2% SDS, pH 8.5) with 10 μl proteinase K (20 mg/ml) at 56°C 
overnight under continuous shaking at 250 rpm. Proteinase K was inactivated by incubating 
the samples for 5 min at 90°C. Samples were centrifuged at 16100 × g in 10°C for 15 min. 
350 μl of the resulting supernatant was collected for the DNA precipitation step by adding 
500 μl of isopropanol. The samples were vortexed and subsequently centrifuged for 5 min at 
16100 × g. The supernatant was removed, and the pellet was washed twice with 70% ethanol. 
The air-dried pellets were then resuspended in 50 μl of TE buffer (10 mM Tris-base, 1 mM 
EDTA, pH 7.5). Heating of DNA samples was performed at 48°C for 30 min. The samples 
were stored at 4°C overnight to achieve a complete resuspension in TE buffer.  
2.2.3.2 Mice genotyping  
Genotyping of STAT1-F77A knock-in mice was performed by combing PCR with a 
restriction fragment length polymorphism (RFLP) technique. The amplified fragment was 
generated by mixing the following components in a single reaction mix for each sample: the 
primer pair stat1-F77A at a final concentration of 0.4 μmol/l, 2.5 μl of 10× reaction buffer, 
0.5 μl of 50 mM MgCl2 solution, 1 μl of dNTP mix (10 μmol/l), 17.25 μl of DNase-, RNase- 
and proteinase-free water, and 0.25 μl of Taq polymerase. In total, 1.5 μl of purified DNA 
solution was added to each reaction. The following PCR program was run for the reaction 
mixtures: 95°C for 3 min, 41 cycles of denaturation at 95°C for 15 s, annealing at 61°C for 15 
s, and extension at 72°C for 15 sec and a final elongation step at 72°C for 7 min. A 1% 
agarose gel was run at 85 mA for 45 min to detect the generated PCR product with the 
UVsolo TS gel documentation system. Digestion of the fragment was performed by 
incubating 5 μl of the product with 0.3 μl of Tsp509I, 1.5 μl of reaction buffer B and 7.2 μl of 
DNase, RNase- and proteinase-free water at 65°C overnight. The digestion reaction mix was 
analyzed with 3% agarose gel run at 85 mA for 60 min. As the F77A mutation causes a loss 
of Tsp509I site, a 234 bp fragment was detected in homozygous mice, while the wildtype-
derived PCR product showed two fragments of equal size.   




2.2.4 RNA analysis 
2.2.4.1 RNA extraction from cell culture and reverse transcription  
Cells were cultured in a starvation medium for 16 h and then stimulated with the respective 
cytokine for the specified time duration. PeqGold total RNA kit (VWR) was used for RNA 
isolation. For adherent cells, culture medium was removed and cells were washed with PBS. 
400 μl of RNA Lysis Buffer T were added directly to the cells on ice. The lysate was 
transferred directly into a DNA Removing Column placed in a 2.0 ml Collection Tube and 
centrifuged at 12000 × g for 1 min at room temperature. The flow-through lysate was 
transferred into a new 1.5 ml tube and an equal volume of 70% ethanol was added to the 
lysate and mixed thoroughly by vortexing. The lysate was then added directly to the 
membrane of a PerfectBind RNA column in a new 2.0 ml collection tube. This assembly was 
centrifuged at 10000 × g for 1 min. The flow-through liquid and the collection tube were 
discarded. The column was placed in a fresh 2.0 ml collection tube and washed by adding 500 
µl of RNA Wash Buffer I followed by a centrifuge step for 15 sec at 10000 × g. A 600 µl of 
completed RNA Wash Buffer II was added to the column and centrifuged for 15 sec at 10000 
× g. The flow-through liquid was discarded, and the wash step was repeated. The column was 
placed in the collection tube and centrifuged for 2 min at 10000 × g to completely dry the 
column matrix. To elute RNA, the column was placed into a fresh 1.5 ml microcentrifuge 
tube and 50 µl of sterile RNase-free water were added directly to the binding matrix and 
centrifuged for 1 min at 5000 × g. The eluted RNA was used directly for cDNA synthesis or 
stored at -80°C. Verso cDNA Synthesis kit was used to reverse transcribe the RNA to create 
cDNA, according to the manufacturer’s instructions. The reaction mixture was as follows: 4 
μl of 5× cDNA synthesis buffer, 2 μl of dNTP mix, 1 μl of RNA primer (anchored Oligo dT), 
1 μl of RT Enhancer, 1 μl of Verso Enzyme Mix, and 3 μl of DNase-, RNase- and proteinase-
free H2O with 8 μl of the purified RNA. The amount of necessary RNA had been determined 
experimentally. The reverse transcription cycling program was 30 min at 42°C, followed by 
inactivation cycle at 95°C for 2 min. The samples were stored at -20°C.  
2.2.4.2 Real-time PCR 
Real-time reverse transcription PCR was used to enable detection and measurement of gene 
transcription products. The PCR cycling program was as follows: 95°C for 4 min, 38 cycles 
of denaturation at 95°C for 45 sec, annealing at 61°C for 45 sec, and extension at 72°C for 
120 sec, with a final elongation at 72°C for 10 min. A master mix was prepared for each 
reaction containing 10 μl of SYBR green, 0.28 μl of each primer (5 μmol/l), and 9.44 μl of 




H2O. Using a semi-skirted 96-well-plate, 19 μl of the master mix was distributed to each well 
with 1 μl of the cDNA reaction sample. GAPDH or HPRT were used as a reference 
housekeeping gene and each sample was run in duplicate. The 2-ΔΔCT method was used to 
analyze the data exported from the realplex ep program. 
2.2.5 Animal experiments 
2.2.5.1 Left anterior descending coronary artery ligation in mice 
STAT1-F77A knock-in mice were used in the myocardial infarction model (LAVES approved 
with reference number 3392 42502-04-13/1226). Surgery was performed on healthy young 
female animals at the age of 8-12 weeks. To provide basic analgesia, metamizol in a final 
concentration of 2 mg/ml was added to drinking water three days before surgery. Mice were 
intraperitoneally anaesthetized with 10 μl/g body weight of 5% Cepetor, 10% midazolam, and 
10% fentanyl in 0.9% NaCl solution and stabilized in the supine position. A small incision of 
the trachea was introduced to insert a tube for artificial respiration (150 μl volume and 150 
strokes/min). To expose the heart, a lateral cut of the pectoral muscles was carried to expose 
the rib cage and spread the fourth intercostal space. Using Ethilon 9-0 BV-4 5.0 mm 3/8c 
EH7448G surgical silk, ligation of the left anterior descending artery was performed to induce 
infarction. Cardiac apex started discoloration into white as a measure of proper occlusion of 
the coronary vessel. Sham-operated mice underwent the same procedure except occlusion of 
the left anterior descending artery. Following successful ligation, retractors were 
disconnected, and suturing of the skin was performed using Prolene 6-0 C-1 13 mm 3/8c 
8889H surgical silk. Intraperitoneal injection of 10 μl/g body weight of narcosis antagonist, 
5% atipamezole, 10% flumazenil, in sterile 0.9% NaCl was administered. Mice were given 
1% buprenorphin in sterile 0.9% NaCl at a dose of 15 μl/g body weight and placed on a pre-
warmed plate at 37°C until awake. Mice were sacrificed through CO2 asphyxiation and hearts 
were collected at day 1 following the surgery. The whole heart was washed with 1× PBS and 
the infarcted areas from the left ventricle were excised with a surgical blade. Samples were 
collected in TRIzol and stored at -80°C until further analysis.  
2.2.5.2 Immunohistochemistry of paraffin-embedded sections  
Mice were sacrificed through CO2 asphyxiation. In LAD ligation experiments, the heart was 
surgically removed and washed in PBS before being stored in 4% formaldehyde solution at 
4°C. After 24 hours, organs were transferred from paraformaldehyde (PFA) into PBS and 
stored at 4°C until further processing. For paraffin embedding, organs were prepared through 




dehydration using ascending concentrations of ethanol and finally pure xylene. Casting 
paraffin-embedded organs in blocks was performed using the EG1160 tissue embedder. The 
blocks were thren cut into sections at 3 μm thickness using the SM 2000 R microtome. 
Tissues were left to stretch in a water bath at 45°C before transferring them into a slide to dry 
at 50°C. To monitor protein expression and localization of proteins in tissues, 
deparaffinization and rehydration were performed by xylene incubation for 15 min twice, then 
by using descending concentrations of ethanol (99%, 96%, 70%, desalted H2O) twice for 2 
min per each solution. Citrate buffer (8.13 mM sodium citrate, pH 6.0) was used for boiling 
the samples for 15 min in a microwave. Samples were cooled on ice followed by washing 
with double-distilled H2O followed by PBS. A solution of 3% H2O2 in PBS was used for 20 
min at 4°C to block peroxidase activity in the tissue sections. A blocking solution consisting 
of 10% FBS in PBS, supplemented with 0.05% Triton X-100, was used to incubate the slides 
for 1 h at room temperature. Primary antibodies were incubated in 10% FBS in PBS overnight 
at 4°C. Tissue slides were washed three times in PBS before secondary antibody incubation, 
which was diluted in 10% FBS in PBS at 1:1000 for 1 h at room temperature. Tissue slides 
were washed four times with PBS followed by incubation for 1 h with streptavidin/peroxidase 
solution diluted at 1:1000 in PBS. A 3,3′-diaminobenzidine (DAP) staining was used at 
development stage (2.5% stock was used by diluting it 1:250 in PBS and adding 0.01% 
H2O2). Reaction time was between 5 to 10 min and was stopped by rinsing with double-
distilled water. Slides were incubated in filtered Mayer’s haemalum solution for 10 min 
followed by washing in running tap water for 10 min. Slides were then washed twice with 
desalted water and dehydrated with ascending concentrations of ethanol (70%, 96%, 99%) 
twice for 2 min each. Tissues were incubated in xylene for 15 min twice. Entellan was used to 
mount the samples to be examined using a light microscope. Dilutions of primary antibodies 
were as the following: anti-STAT1; 1:200, anti-STAT3; 1:200. 
  




Table 18: Evaluation of STAT staining distribution and intensity in heart tissue  
0 No specific staining 
1 Less than half of the left ventricle 
2 50% to 90% of the left ventricle 
3 Entire left ventricle but little or no infiltration of the septum or right ventricle 
4 Entire left ventricle and moderate to significant infiltration of the right 
ventricle or the septum 
  
0 No specific staining 
1 Single cells at low density 
2 Small accumulations, moderate density 
3 Many or large accumulations 
4 High, even density of positively stained cells 
2.2.6 RNA sequencing and analysis 
Sequencing of RNA samples was conducted at the Microarray and Deep-Sequencing Facility 
(Transcriptome and Genome Analysis Laboratory (TAL), Göttingen). RNA was extracted 
using TRIzol isolation protocol. Quality and integrity of RNA samples were assessed with a 
fragment analyzer using the standard sensitivity RNA analysis kit. All samples selected for 
sequencing exhibited an RNA integrity number over 8. For library preparation, 500 ng of total 
RNA was used. Samples were immediately fragmented (300 bp) and cDNA subsequently 
synthesized. RNA-seq libraries were performed using TruSeq stranded mRNA prep kit with a 
modified strand-specific massively-parallel cDNA sequencing mRNA-seq protocol. The 
protocol was first optimized during the ligation step by diluting the adapters concentration to 
increase ligation efficiency (>94%), and finally reducing the number of PCR cycles to avoid 
PCR duplication artifacts as well as primer dimers in the final library product. Using strand-
specificity protocols, differences in coverage, agreement with known annotations, and 
accuracy for expression profiling were observed. For accurate quantitation of cDNA libraries, 
a fluorometric-based system called QuantiFluor dsDNA was used. The size of final cDNA 
libraries was determined by using the dsDNA 905 reagent kit, exhibiting a sizing of 300 bp in 
average. Libraries were pooled and sequenced on an Illumina HiSeq 4000 generating 50 bp 
single-end reads (30-40 million reads/sample). Generation of raw data files and their quality 
check were performed, and sequence images were transformed with BaseCaller to bcl files, 




which was demultiplexed to FASTQ files with bcl2fastq. The sequencing quality was asserted 
using FastQC. Mapping of sequenced reads and read counting for all samples was performed. 
Sequences were aligned to the reference genome Mus musculus mm10 (version 89) using the 
STAR aligner, allowing for 2 mismatches within 50 bases (Dobin et al., 2013). Subsequently, 
read counting was performed using featureCounts (Liao et al., 2014). Differential expression 
analysis was also performed and read counts were analyzed in the R/Bioconductor 
environment (version 3.4.2) using DESeq2 package (Love et al., 2014). Candidate genes were 
filtered using an absolute log2 fold-change >1 and FDR(False Discovery Rate)-corrected p-
value <0.05. Gene annotation was performed using Mus musculus entries via biomaRt R 
package (Durinck et al., 2009). The following R packages were used for gene set enrichment 
analysis and data visualization: ggplot2, kableExtra, pheatmap, d3heatmap, gage, dplyr, 
pathview, biomaRt, grid, VennDiagram, and ggrepel. 
2.2.7 Parallel plate flow chamber assay 
All cells were resuspended in HL-60 media (RPMI-1640, 10% FCS, 1% penicillin/ 
streptomycin) supplemented with 25 mM HEPES buffer prior to the perfusion assay. Addition 
of HEPES provided supplemental buffering at a pH 7.2 through 7.6, as CO2 supply was 
absent in the assay. A monolayer of human umbilical vein endothelial cell (HUVEC) was 
grown to confluency and stimulated overnight with 10 ng/ml TNF-α. On the next day, 
analysis of HL-60 cells interacting with HUVEC was performed at 37°C in a 5% CO2 
incubator and visualized using Olympus IX81 time-lapse inverted fluorescence microscope 
linked to a Hamamatsu C10600 ORCA-R2 digital video camera. A Harvard syringe pump 
generated a physiological shear stress of blood flow with a flow rate of 0.30 ml/min which 
corresponds to 1.5 dyn/cm3. HL-60 cells were perfused at a density of 1x106 cells/ml over 
TNF-α activated HUVEC, grown in plastic dishes for 25 minutes. The footage was recorded 
from the moment the cells were visible using a 4×objective. Images were saved into a video 
file using Volocity Imaging software.  
2.2.8 Statistical analysis  
IBM SPSS and R statistical software were used. Descriptive statistics were calculated from 
the data (e.g. mean, confidence interval of the mean, median, minimum, maximum, first 
quantile, third quantile, standard deviation, and standard error). A t-test for independent 
samples was used to compare the means for two groups. A p-value of 0.05 was chosen as 










3.1 Echocardiographic analysis demonstrated beneficial outcomes in STAT1-F77A mice 
after myocardial infarction 
The left ventricular size and function of STAT1-F77A and wild-type mice were assessed 
using sham-operated mice (as control) or mice that were subjected to ligation of the left 
anterior descending coronary artery (LAD), as published in Theresa Riebling´s doctoral 
thesis, summarized in Tables 21 and 22 and depicted in Figure 4. The left ventricular end-
systolic inner diameter in STAT1-F77A mice was significantly decreased as compared to 
wild-type mice on the third day (mean=3.92 mm, 95%-CI=3.59–4.25 mm vs mean=4.39 mm, 
95%-CI=4.15–4.64 mm, p=0.036) and at the end of the first week (mean=4.38 mm, 95%-
CI=3.70–5.05 mm vs mean=5.40 mm, 95%-CI=4.60–6.20 mm, p=0.049) after LAD ligation. 
Similarly, the left ventricular end-systolic area in STAT1-F77A mice was significantly lower 
as compared to wild-type mice on the third day (mean=10.24 mm2, 95%-CI=8.92–11.55 mm2 
vs mean=12.79 mm2, 95%-CI=11.54–14.05 mm2, p=0.0068) and at the end of the first week 
(mean=11.55 mm2, 95%-CI=7.79–15.31 mm2 vs mean=18.09 mm2, 95%-CI=13.54–22.65 
mm2, p=0.03) after LAD ligation. The systolic epicardial area was reduced at day 7 post-MI 
compared to wild-type mice (mean=22.6 mm2, 95%-CI=18.36–26.84 mm2 vs mean=29.52 
mm2, 95%-CI=24.32–34.71 mm2, p=0.039). Additionally, the left ventricular end-diastolic 
inner diameter in STAT1-F77A mice was significantly decreased on the third day compared 
to wild-type mice (mean=4.39 mm, 95%-CI=4.14–4.64 mm vs mean=4.79 mm, 95%-
CI=4.64–4.94 mm, p=0.0035). Correspondingly, the end-diastolic area in STAT1-F77A mice 
was significantly lower on the third day compared to wild-type mice (mean=13.57 mm2, 










Table 19 illustrates the most common parameters used to evaluate the function of the left 
ventricle including the equations used to calculate them, which are fractional area shortening 
(FAS), fractional shortening (FS), end-systolic volume (Vols), end-diastolic volume (Vold), 
and ejection fraction (EF). In our data, the fractional area shortening of the left ventricle in 
STAT1-F77A mice was significantly increased at the end of the first week following 
myocardial infarction as compared to wild-type mice (mean=26.92%, 95%-CI=20.36–33.48% 
vs mean=16.13%, 95%-CI=9.70–22.56%, p=0.024). Likewise, the ejection fraction of the left 
ventricle in STAT1-F77A mice was significantly improved at day 7 following MI as 
compared to wild-type mice (mean=30.11%, 95%-CI=22.64–37.57% vs mean=18.6%, 95%-
CI=11.26–25.95%, p=0.03). Furthermore, the end-systolic volume of the left ventricle in 
STAT1-F77A mice was significantly decreased as compared to wild-type mice on the third 
day (mean=62.44 mm3, 95%-CI=52.42–72.45 mm3 vs mean=79.49 mm3, 95%-CI=69.93–
89.05 mm3, p=0.039) and at the end of the first week (mean=72.00 mm3, 95%-CI=42.88–
101.12 mm3 vs mean=119.69 mm3, 95%-CI=84.14–155.23 mm3, p=0.039). Moreover, the 
end-diastolic volume of the left ventricle in STAT1-F77A mice was significantly lower on the 
third day as compared to wild-type mice (mean=85.82 mm3, 95%-CI=74.52–97.12 mm3 vs 
mean=101.90 mm3, 95%-CI=93.03–110.78 mm3, p=0.045). 
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Figure 4: Echocardiographic assessment of hemodynamic parameters in wild-type and STAT1-
F77A knock-in mice. Before LAD ligation (n=23 and n=23, respectively), 3 days, (n=12 versus 
n=12), one week (n=9 versus n=8) and four weeks (n=7 versus n=8) following LAD ligation.  *p ≤ 










Table 20: Measurements of important structural cardiac parameters in wild-type and STAT1-
F77A knock-in mice.  































Pre-MI WT 3.50 (3.38-3.63) 3.15 3.26 3.47 3.73 4.15 0.99 
STAT1-F77A 3.47 (3.34-3.59) 2.76 3.3 3.5 3.68 3.98 
Day 3 WT 4.39 (4.15-4.64) 3.58 4.19 4.4 4.51 5.03 0.036* 
STAT1-F77A 3.92 (3.59-4.25) 2.95 3.68 3.79 4.25 4.71 
Week 1 WT 5.40 (4.6-6.20) 3.42 5.05 5.51 6.35 6.68 0.049* 
STAT1-F77A 4.38 (3.7-5.05) 3.43 3.72 4.3 4.86 5.86 
Week 4 WT 5.55 (4.26-6.83) 3.83 4.32 5.82 6.75 7.03 0.52 































Pre-MI WT 4.29 (4.18-4.4) 3.83 4.14 4.25 4.39 5.01 0.52 
STAT1-F77A 4.31 (4.22-4.4) 3.94 4.19 4.35 4.46 4.62 
Day 3 WT 4.79 (4.64-4.94) 4.33 4.68 4.76 4.94 5.19 0.0035* 
STAT1-F77A 4.39 (4.14-4.64) 3.46 4.25 4.56 4.62 4.82 
Week 1 WT 5.60 (5.05-6.16) 4.36 5.33 5.66 6.09 6.86 0.061 
STAT1-F77A 4.96 (4.43-5.49) 4.18 4.34 5.06 5.36 5.98 
Week 4 WT 5.9 (4.94-6.85) 4.57 5.1 5.83 6.8 7.09 0.45 















Pre-MI WT 8.28 (7.68-8.88) 6.43 7.34 8.2 8.98 11.96 0.38 
STAT1-F77A 7.92 (7.32-8.52) 5.77 6.97 7.8 8.54 11.55 
Day 3 WT 12.79 (11.54-14.05) 9.1 11.64 12.93 14.17 15.91 0.0068* 
STAT1-F77A 10.24 (8.92-11.55) 6.64 9.27 10.09 11.11 13.27 
Week 1 WT 18.09 (13.54-22.65) 8.76 14.42 17.14 21.62 27.96 0.030* 
STAT1-F77A 11.55 (7.79-15.31) 6.17 8.83 11.7 12.22 21.12 
Week 4 WT 20.64 (12.79-28.50) 9.18 13.38 23.19 28.01 29.35 0.38 


















Pre-MI WT 12.2 (11.6-12.81) 10.01 11.2 12.27 12.79 15.89 0.95 
STAT1-F77A 12.22 (11.55-12.90) 9.47 11.56 12.01 12.96 16.62 
Day 3 WT 15.83 (14.81-16.85) 12.3 15.52 16.34 16.79 17.81 0.013* 
STAT1-F77A 13.57 (12.17-14.98) 9 12.39 13.63 15 16.49 
Week 1 WT 21.29 (16.79-25.79) 12.7 19.4 22.02 24.2 32.24 0.061 
STAT1-F77A 15.54 (11.5-19.58) 10.72 12.13 15.15 16.6 25.74 
Week 4 WT 24.68 (17.06-32.31) 12.34 18.73 25.62 32.24 32.91 0.27 



















) Pre-MI WT 18.19 (17.4-18.98) 15.93 16.73 17.34 19.23 22.66 0.29 
STAT1-F77A 18.61 (17.78-19.44) 14.57 17.71 18.4 19.58 23.67 
Day 3 WT 25.02 (23.57-26.47) 20.73 23.83 24.75 26.35 28.62 0.17 
STAT1-F77A 23.21 (20.18-26.24) 14.12 21.04 22.91 25.33 31.5 
Week 1 WT 29.52 (24.32-34.71) 20.27 25.03 29.1 32.28 41.8 0.039* 
STAT1-F77A 22.6 (18.36-26.84) 17.17 18.47 23.15 24.22 32.66 
Week 4 WT 34.49 (26.27-42.72) 21.26 27.83 38.71 40.83 44.16 0.15 
STAT1-F77A 28.97 (17.9-40.04) 17.07 20.87 25.86 30.56 59.27 
Before MI (n=23 and n=23, respectively), and at different time points after MI: 3 days, (n=12 versus 
n=12), one week (n=9 versus n=8) and four weeks (n=7 versus n=8). Mean, lower and upper quartile 









Table 21: Assessment of important functional cardiac parameters in wild-type and STAT1-
F77A knock-in mice 

















Pre-MI WT 18.35 (16.43-20.28) 10.84 15.16 17.19 22.27 26.06 0.49 
STAT1-F77A 19.54 (17.19-21.90) 10.74 15.84 18.14 22.84 31.27 
Day 3 WT 9.47 (5.85-13.08) 3.11 4.81 8.56 12.98 21.21 0.56 
STAT1-F77A 10.88 (7.06-14.71) 2.28 7.13 12.96 14.1 18.8 
Week 1 WT 6.79 (1.82-11.77) 0.55 2.58 4.93 9.81 21.67 0.11 
STAT1-F77A 12.23 (7.50-16.95) 1.88 9.22 13.13 14.95 21.19 
Week 4 WT 7.31 (0.02-14.6) 0.13 0.93 2.34 14.81 17.24 0.35 


















) Pre-MI WT 32.38 (29.86-34.91) 21.25 30.93 32.38 35.73 45.46 0.22 
STAT1-F77A 35.26 (32.23-38.29) 18.62 32.04 33.33 39.07 49.9 
Day 3 WT 19.33 (14.07-24.58) 8.9 10.51 19.53 26.17 30.58 0.21 
STAT1-F77A 24.72 (20.16-29.29) 15.97 20.02 25.76 28.74 36.84 
Week 1 WT 16.13 (9.7-22.56) 6.98 10.65 14.09 22.14 31.01 0.024* 
STAT1-F77A 26.92 (20.36-33.48) 17.96 20.88 26.2 29.84 42.42 
Week 4 WT 18.52 (10.15-26.9) 9.49 11.6 13.86 25.2 32.73 0.45 














Pre-MI WT 37.82 (35.23-40.41) 25.52 35.6 37.46 42.4 49.68 0.11 
STAT1-F77A 41.08 (38.23-43.93) 25.37 37.76 39.65 45.43 54.71 
Day 3 WT 22.27 (17.45-27.08) 11.65 15.57 23.04 28.93 31.61 0.10 
STAT1-F77A 27.39 (22.25-32.54) 16.9 20.91 27.53 34.71 37.89 
Week 1 WT 18.60 (11.26-25.95) 7.84 11.14 16.59 24.23 36.59 0.030* 
STAT1-F77A 30.11 (22.64-37.57) 18.69 24.41 29.05 34.08 47 
Week 4 WT 21.55 (12.64-30.46) 11.25 14.41 16.54 30.26 33.76 0.52 



















Pre-MI WT 48.50 (44.3-52.7) 33.58 42.47 46.68 54.67 75.21 0.25 
STAT1-F77A 45.08 (41.36-48.8) 32.28 40.73 44.56 50.86 64.85 
Day 3 WT 79.49 (69.93-89.05) 55.23 71.23 81.4 85.01 108.4 0.039* 
STAT1-F77A 62.44 (52.42-72.45) 39.05 54.82 60.11 69.01 86 
Week 1 WT 119.69 (84.14-155.23) 46.72 93.47 108.07 148.48 194.47 0.039* 
STAT1-F77A 72.00 (42.88-101.12) 36.61 52.32 66.16 78.59 148.88 
Week 4 WT 145.13 (83.69-206.57) 57.03 88.86 161.71 200.87 217.71 0.27 



















  Pre-MI WT 77.69 (72.7-82.68) 59.02 72.24 76.89 83.34 110.86 0.78 
STAT1-F77A 76.46 (71.59-81.32) 56.03 70.81 76.27 81.72 106.57 
Day 3 WT 101.9 (93.03-110.78) 75.72 94.42 104.22 112.07 124.1 0.045* 
STAT1-F77A 85.82 (74.52-97.12) 53.89 75.85 83.24 97.68 107.4 
Week 1 WT 143.94 (108.35-179.53) 73.67 125.49 142.63 167.09 228.05 0.061 
STAT1-F77A 100.36 (68.71-132.01) 66.42 77.08 90.74 110.85 183.09 
Week 4 WT 178.84 (116.48-241.2) 85.47 127.35 182.2 235.29 258.94 0.22 
STAT1-F77A 139.31 (66.55-212.07) 66.05 86.83 109.76 162.51 334.46 
Before MI (n=23 and n=23, respectively), and at different time points after MI: 3 days, (n=12 versus 
n=12), one week (n=9 versus n=8) and four weeks (n=7 versus n=8). Mean, lower and upper quartile 









3.2 Expression of STAT1 and STAT3 in both cardiomyocytes and infiltrating immune 
cells after myocardial infarction 
In order to analyze the expression profile of STAT1 and STAT3 proteins, immunohisto-
chemical staining was performed in sections of infarcted area for STAT1-F77A and wild-type 
mice undergoing LAD ligation or sham operation. Immunohistochemical analysis of staining 
intensity and distribution revealed expression of STAT1 and STAT3 in both cardiomyocytes 
and infiltrating immune cells at day 3 post-MI, while no significant differences in their 
expression levels were identified among the two groups (Figure 5). 
      WT                       WT/F77A  F77A/F77A 
 
 
Figure 5: Immunohistochemical analysis of STAT1 and STAT3 expression in the infarcted area 
at day 3 post-MI. Semi-quantitative analysis of STAT staining distribution and intensity are 









3.3 Transcriptomic analysis of F77A mice in a LAD ligation model  
With the aim to analyze the left ventricular global transcriptional profile, we constructed 12 
RNA libraries and sequenced them (Figure 6). Samples were collected from sham-operated or 
LAD-ligation-operated mice expressing either wild-type or mutant STAT1. The quality 
controls as well as the number of pooled mice for extracted RNA are shown in Table 22 and 
Figure 7.  
 












































Table 22: Quality assessment of total RNA in the infarcted heart tissue samples.  
Sample ID N Concentration 
(ng/µl) 
Yield (µg) A260/A280 A260/A230 RIN 28s/18s 
WT-Sham-1 4 711.46±197.94 35.57±9.9 1.92±0.05 1.61±0.33 9.35±0.16 1.40±0.19 
WT-Sham-2 4 728.99±68.55 36.45±3.43 1.88±0.04 1.35±0.28 9.88±0.08 1.33±0.22 
WT-Sham-3 3 910.82±130.15 45.54±6.51 1.97±0.03 1.73±0.33 10.00±0 1.43±0.29 
WT-MI-1 4 341.19±59.23 17.06±2.96 1.87±0.01 2.08±0.07 8.35±0.28 1.65±0.27 
WT-MI-2 4 524.07±80.14 26.20±4.01 1.90±0.02 1.66±0.25 9.45±0.06 1.73±0.2 
WT-MI-3 3 348.60±45.23 17.43±2.26 1.83±0.01 2.01±0.06 9.87±0.13 1.67±0.09 
F77A-Sham-1 2 493.65±12.11 24.68±0.61 1.89±0.07 1.54±0.52 9.00±0.6 1.40±0 
F77A-Sham-2 1 435.19 21.76 1.88 2.19 10.00 1.20 
F77A-Sham-3 1 768.92 38.45 1.95 1.44 10.00 1.70 
F77A-MI-1 4 316.85±59.01 15.84±2.95 1.86±0.01 1.70±0.24 8.03±0.08 1.35±0.05 
F77A-MI-2 3 331.88±82.68 16.59±4.13 1.80±0.06 1.61±0.51 8.23±0.03 1.27±0.09 










Figure 7: Separation of high-quality total RNA extracted from infarcted heart tissue. A) The 
purple and pink peaks represent the large (28S rRNA) and small (18S rRNA) ribosomal RNA peaks, 
respectively. The small RNA region includes the peaks and smears below 200 nucleotides, which is 
well defined, as these are the small and large rRNA subunits, providing a high RQN (RNA quality 
number) of 10. All samples selected for sequencing exhibited an RNA integrity number over 8. B) 
Separation of HS RNA Ladder on a Fragment Analyzer using the Standard Sensitivity RNA analysis 









3.4 Identification of differentially expressed genes in STAT1-F77A and wild-type mice at 
day 1 post-myocardial infarction  
To identify differentially expressed genes (DEGs) following MI in wild-type and mutant 
mice, a |log2 (fold change) | >1 and a p-value < 0.05 were used as standards. We identified 
1912 differentially expressed genes in wild-type mice. However, as a consequence of LAD 
ligation, the number of differentially regulated genes was 4055 genes in STAT1-F77A, which 
is significantly higher as compared to wild-type mice. Furthermore, subsequent to MI 
induction, we found 194 DEGs that were unique in wild-type mice but were not significantly 
modulated in STAT1-F77A mice, and 2337 DEGs that are unique in STAT1-F77A mice, but 
not changed in wild-type mice post-MI. Moreover, we identified 1718 DEGs that were 
commonly expressed in wild-type and STAT1-F77A mice. Of the 2337 uniquely 
differentially expressed genes in the STAT1-F77A following MI, there were 909 upregulated 
and 1428 downregulated genes, whereas, of the 194 uniquely differentially expressed genes in 
wild-type animals, there were 111 upregulated and 83 downregulated genes (Figure 8). The 
hierarchical clustering of RPKM (reads per kilobase of transcript per million mapped reads) 
values of the differentially expressed genes for both wild-type (MI vs sham) and STAT1-
F77A (MI vs sham) comparisons in the four groups (wild-type sham, wild-type MI, STAT1-
F77A sham, STAT1-F77A MI) are shown in Figure 9.  
The top 10 genes that are differentially expressed in wild-type following MI are the 
following: Hspa1a (heat shock protein family a (hsp70) member 1a), Hspa1b (heat shock 
protein family a (hsp70) member 1b), Fgf23 (fibroblast growth factor 23), Cxcl2 (C-X-C 
motif chemokine ligand 2), Ngp (neutrophilic granule protein), Fosb (fosb proto-oncogene, 
ap-1 transcription factor subunit), Aa467197 (expressed sequence aa467197), Cxcl10 (C-X-C 
motif chemokine ligand 10), Ccl4 (c-c motif chemokine ligand 4), Cd177 (human neutrophil 
alloantigen 2a). Table 23 illustrates the top 20 differentially expressed genes in wild-type 
(LAD ligation vs sham) comparison with the log2fold change, padj, log10padj and baseMean 










Figure 8: The number of unique genes that are upregulated or downregulated in wild-type and 
STAT1-F77A following LAD ligation. 
 
Table 23: Top 20 genes differentially expressed in wild-type following LAD ligation  
Gene log2fold change  padj  log10padj  baseMean  
Hspa1a  3.77  9.56e-11  1.00e+01  1851.08  
Hspa1b  3.66  4.59e-10  9.34e+00  2979.38  
Fgf23  3.65  1.91e-10  9.72e+00  216.89  
Cxcl2  3.62  4.60e-11  1.03e+01  1167.84  
Ngp  3.43  2.40e-08  7.62e+00  49.94  
Fosb  3.39  1.53e-08  7.82e+00  478.94  
AA467197  3.31  4.37e-08  7.36e+00  690.60  
Cxcl10  3.28  3.62e-09  8.44e+00  422.35  
Ccl4  3.27  1.02e-09  8.99e+00  393.55  
Cd177  3.25  1.28e-09  8.89e+00  406.20  
Thbs1  3.24  5.26e-11  1.03e+01  12485.02  
Hcar2  3.23  1.46e-08  7.84e+00  337.96  
Cxcl3  3.21  1.20e-08  7.92e+00  1422.77  
Asprv1  3.21  6.28e-11  1.02e+01  290.54  
Ptgs2  3.18  3.82e-08  7.42e+00  1411.21  
Slc7a11  3.17  1.36e-08  7.87e+00  422.98  
Retnlg  3.16  1.20e-11  1.09e+01  797.23  
Il6  3.16  7.46e-09  8.13e+00  532.09  
Selp  3.16  5.26e-11  1.03e+01  1177.32  










In addition, the top 10 genes that are differentially expressed in STAT1-F77A (LAD ligation 
vs sham) comparison are the following: Fgf23 (fibroblast growth factor 23), Cxcl3 (C-X-C 
motif chemokine ligand 3), Slfn4 (schlafen 4), Rab44 (rab44, member ras oncogene family), 
Cxcl2 (C-X-C motif chemokine ligand 2), Cd177 (human neutrophil alloantigen 2a), Gm5483 
(predicted gene 5483), Il1r2 (interleukin 1 receptor type 2), Cd300lf (cd300 molecule like 
family member f), Slfn1 (schlafen family member 12). Table 24 illustrates the top 20 
differentially expressed genes in STAT1-F77A following LAD ligation with the log2fold 
change, padj, log10padj and baseMean values shown.   
 
Table 24: Top 20 genes differentially expressed in STAT1-F77A following LAD ligation  
Gene log2fold change  padj  log10padj  baseMean  
Fgf23  4.89  1.29e-19  1.89e+01  216.89  
Cxcl3  4.76  9.07e-20  1.90e+01  1422.77  
Slfn4  4.64  8.59e-21  2.01e+01  5478.06  
Rab44  4.52  1.37e-17  1.69e+01  788.41  
Cxcl2  4.51  1.38e-18  1.79e+01  1167.84  
Cd177  4.49  3.60e-19  1.84e+01  406.20  
Gm5483  4.45  1.53e-16  1.58e+01  136.50  
Il1r2  4.41  2.53e-17  1.66e+01  1517.34  
Cd300lf  4.40  4.25e-22  2.14e+01  1932.80  
Slfn1  4.34  9.07e-20  1.90e+01  1233.29  
Ptgs2  4.27  2.51e-15  1.46e+01  1411.21  
Cxcr2  4.19  3.23e-18  1.75e+01  1119.46  
Slc7a11  4.19  9.62e-16  1.50e+01  422.98  
Hcar2  4.18  5.19e-15  1.43e+01  337.96  
Sh2d5  4.15  1.04e-13  1.30e+01  925.10  
Adamts4  4.13  5.50e-14  1.33e+01  3382.60  
Trem1  4.13  2.77e-17  1.66e+01  631.05  
Hspa1a  4.12  5.50e-14  1.33e+01  1851.08  
Mirt2  4.12  4.52e-13  1.23e+01  69.10  













Figure 9: Hierarchical clustering of RPKM values in wild-type and STAT1-F77A mice in both 
sham-operated and LAD-ligation-operated mice. The first heat map was generated using the list of 
genes that are differentially expressed in wild-type (MI vs sham) comparison (in total 1912 genes). 
The second heat map was generated using genes that are differentially expressed in STAT1-F77A (MI 











To depict the distribution of differentially regulated genes unique in unaffected myocardium 
and infarcted areas from the hearts of wild-type and STAT1-F77A mice, a Venn diagram 
representation was used. Figure 10 demonstrates the number of differentially expressed genes 
found in the following four groups: wild-type (MI vs sham) upregulated, wild-type (MI vs 
sham) downregulated, STAT1-F77A (MI vs sham) upregulated, and STAT1-F77A (MI vs 
sham) downregulated. The overlap of the two ovals in the top of the diagram is 1598, which 
is the number of differentially expressed genes that are shared between wild-type (MI vs 
sham) upregulated and F77A (MI vs sham) upregulated lists. The overlap of the two ovals in 
the bottom of the diagram is 120, which is the number of the differentially expressed genes 
that are shared between the wild-type (MI vs sham) downregulated and F77A (MI vs sham) 
downregulated lists. The areas of no overlap represent the number of uniquely (not shared) 





Figure 10: The numbers of differentially expressed genes in the infarcted area common and 
unique in wild-type and STAT1-F77A mice. The following pairwise comparisons are shown: wild-
type (MI vs sham) upregulated, wild-type (MI vs sham) downregulated, STAT1-F77A (MI vs sham) 









Additionally, we used volcano plots to represent DESeq2 differential expression analysis 
results in animals who underwent ligation of the LAD vs sham operation in wild-type and 
STAT1-F77A mice, with y-axis as -log10-adjusted p-value and the x-axis as the log2-fold 
change (Figure 11 and Figure 12). In each plot, every point represents an individual 
transcript. The vertical lines represent a threshold of 1-fold change, either upregulated (right 
side) or downregulated (left side), while the horizontal lines represent an adjusted p-value 
<0.05. Colored points correspond to the uniquely differentially expressed genes in the 
following groups: 111 genes in wild-type MI vs sham upregulated (dark-turquoise), 83 genes 
in wild-type MI vs sham downregulated (light-turquoise), 909 genes in F77A MI vs sham 
upregulated (dark-orange), 1428 genes in F77A MI vs sham downregulated (light-orange), 





Figure 11: Volcano plot representation of differentially expressed genes in wild-type and 
STAT1-F77A mice post-myocardal infarction vs sham operated. Colored points correspond to 
uniquely upregulated or downregulated genes in the following pairwise comparisons: wild-type (MI 
vs sham) upregulated, wild-type (MI vs sham) downregulated, STAT1-F77A (MI vs sham) 












Figure 12: Volcano plot representation of uniquely differentially expressed genes  in wild-type 
and STAT1-F77A (MI vs sham operated). (A) STAT1-F77A MI vs sham comparison. Colored 
points correspond to uniquely upregulated or downregulated genes in the STAT1-F77A MI vs sham 
comparison. The same genes are highlighted in the wild-type MI vs sham plots separately. (B) Wild-
type MI vs sham. Colored points correspond to uniquely upregulated or downregulated genes in the 
wild-type MI vs sham comparison and the same genes are highlighted in the STAT1-F77A MI vs sham 
plots separately. (C) Colored points correspond to non-differentially expressed genes in the wild-type 









Tables 25 and 26 illustrate the top 20 uniquely upregulated or downregulated differentially 
expressed genes in wild-type (LAD ligation vs sham) comparison, respectively.  
 
Table 25: Top 20 uniquely upregulated genes in wild-type following LAD ligation  
Gene  log2fold change  padj  log10padj  baseMean  
Olfm2  1.67  1.10e-02  1.96e+00  7.21  
Unc13c  1.62  4.75e-03  2.32e+00  18.22  
Gp5  1.61  1.50e-02  1.82e+00  17.47  
Cacna1e  1.57  6.56e-04  3.18e+00  18.02  
Mospd4  1.57  2.77e-02  1.56e+00  4.27  
Jakmip1  1.57  6.29e-03  2.20e+00  15.90  
1700016P03Rik  1.56  2.92e-02  1.53e+00  7.58  
Snord58b  1.54  2.51e-02  1.60e+00  5.60  
Depdc1b  1.53  1.47e-02  1.83e+00  6.53  
Ighg2b  1.53  3.14e-02  1.50e+00  3.81  
Crhbp  1.52  3.23e-02  1.49e+00  3.59  
Col2a1  1.52  1.90e-02  1.72e+00  6.18  
Lrtm2  1.52  1.00e-02  2.00e+00  13.59  
Gm10288  1.51  2.55e-02  1.59e+00  9.14  
Igha  1.51  3.18e-03  2.50e+00  46.31  
Spic  1.50  8.90e-03  2.05e+00  11.16  
Igsf11  1.50  4.84e-03  2.32e+00  44.37  
Gm17619  1.50  3.40e-02  1.47e+00  4.77  
Gm23301  1.48  5.33e-03  2.27e+00  18.45  
Cebpd  1.48  1.11e-03  2.95e+00  1707.34  
 
Table 26: Top 20 uniquely downregulated genes in wild-type following LAD ligation  
Gene (wild-type unique down) log2fold change  padj  log10padj  baseMean  
Slitrk6  -1.01  3.86e-02  1.41e+00  50.93  
Dact2  -1.01  3.85e-02  1.41e+00  51.37  
Adamts17  -1.01  8.55e-03  2.07e+00  44.52  
Ccdc173  -1.01  1.92e-02  1.72e+00  38.83  
Ripk4  -1.02  3.48e-02  1.46e+00  17.04  
Gm17080  -1.03  2.89e-02  1.54e+00  33.97  
Gm15853  -1.03  1.45e-02  1.84e+00  30.76  
E330037G11Rik  -1.03  2.69e-02  1.57e+00  19.74  
Fgf14  -1.05  3.86e-02  1.41e+00  70.66  
Pdzrn4  -1.05  2.62e-02  1.58e+00  133.42  
Rassf9  -1.05  4.06e-02  1.39e+00  626.03  
Ict1os  -1.06  2.60e-02  1.59e+00  17.01  
Gm28523  -1.06  1.60e-02  1.80e+00  56.84  
Gm43075  -1.06  4.64e-02  1.33e+00  12.46  
Gm45809  -1.06  4.61e-02  1.34e+00  10.64  
Gm6581  -1.06  4.93e-02  1.31e+00  11.72  
BC065397  -1.07  1.10e-02  1.96e+00  92.85  
5033417F24Rik  -1.07  1.92e-02  1.72e+00  23.30  
Syt15  -1.08  2.79e-02  1.55e+00  43.60  










Tables 27 and 28 illustrate the top 20 uniquely upregulated or downregulated differentially 
expressed genes in STAT1-F77A (LAD ligation vs sham) comparison, respectively. 
  
 
Table 27: Top 20 uniquely upregulated genes in STAT1-F77A following LAD ligation  
Gene (F77A unique UP) log2fold change  padj  log10padj  baseMean  
Tnfsf15  2.54  6.45e-05  4.19e+00  3.93  
Trdc  2.47  2.43e-05  4.61e+00  10.88  
Gm10800  2.39  6.96e-05  4.16e+00  140.52  
Gm19610  2.29  1.06e-04  3.97e+00  6.86  
Muc2  2.20  6.83e-05  4.17e+00  26.84  
Khdc3  2.20  5.70e-04  3.24e+00  4.04  
Gm40304  2.20  5.74e-04  3.24e+00  4.81  
Gm15922  2.19  4.36e-04  3.36e+00  10.23  
Gm38575  2.19  6.16e-04  3.21e+00  3.21  
Gm10801  2.18  4.00e-04  3.40e+00  16.00  
Gm16853  2.18  3.40e-04  3.47e+00  4.66  
Slc22a20  2.17  6.31e-04  3.20e+00  3.17  
5830428M24Rik  2.17  1.46e-04  3.84e+00  19.90  
Chrnb3  2.16  7.11e-04  3.15e+00  5.36  
Gpr15  2.16  1.95e-04  3.71e+00  7.39  
Irgc1  2.15  5.52e-04  3.26e+00  4.32  
Gm10717  2.15  6.31e-04  3.20e+00  4.74  
Gm13748  2.14  3.99e-04  3.40e+00  8.37  
E230014E18Rik  2.13  1.18e-04  3.93e+00  16.59  
Gm42141  2.12  5.47e-04  3.26e+00  9.37  
 
Table 28: Top 20 uniquely downregulated genes in STAT1-F77A following LAD ligation  
Gene  log2fold change  padj  log10padj  baseMean  
Cd36  -1.00  4.51e-03  2.35e+00  72449.49  
Rmnd1  -1.00  6.19e-03  2.21e+00  851.78  
Gnb3  -1.00  1.24e-02  1.91e+00  168.96  
Dusp23  -1.00  8.89e-05  4.05e+00  454.24  
Rgs5  -1.00  6.41e-03  2.19e+00  22728.88  
Nipal3  -1.00  5.40e-03  2.27e+00  1366.59  
Zfp606  -1.00  3.36e-03  2.47e+00  613.67  
Myom2  -1.00  2.38e-03  2.62e+00  69623.68  
Macrod1  -1.00  2.76e-04  3.56e+00  5880.34  
D630003M21Rik  -1.00  2.89e-02  1.54e+00  465.21  
Uqcrfs1  -1.00  8.79e-04  3.06e+00  28587.72  
Fam13c  -1.00  1.72e-02  1.76e+00  291.44  
Cxxc4  -1.00  2.06e-02  1.69e+00  183.16  
Kcnb1  -1.00  5.70e-03  2.24e+00  2996.43  
Gm9947  -1.00  4.03e-02  1.39e+00  10.70  
Camk2b  -1.00  2.07e-03  2.68e+00  573.18  
Cd59b  -1.00  6.76e-03  2.17e+00  54.54  
Gm10604  -1.00  4.75e-02  1.32e+00  12.84  
Gm13657  -1.00  4.62e-02  1.34e+00  17.66  









3.5 Gene set enrichment analysis identified common and unique pathways associated 
with myocardial infarction  
To gain biological insight into the physiological role of cooperative DNA binding of STAT1 
transcription factor on the global transcriptional regulation in acute myocardial infarction, we 
aimed to characterize the transcriptome of normal and infarcted heart tissue on day 1 from 
both wild-type and STAT1-F77A mice following LAD ligation. The top enriched pathways in 
the myocardial tissue of wild-type and STAT1-F77A animals post-MI were identified. To 
explore shared functions among differentially expressed genes, a common approach is to 
integrate the biological information, such as Gene Ontology (GO) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG), for classifying major biological themes of gene sets. In these 
analyses, we tested for coordinated differential expression over gene sets from KEGG 
pathways rather than changes of individual genes. Generally applicable gene-set enrichment 
analysis was performed using the GAGE package on the differentially expressed genes. The 
log2-fold changes for all the genes from the DEseq2 differential expression analysis were 
used as an input for GAGE analysis. We assumed that perturbations over a specific pathway 
may propose mechanistic changes post-myocardial infarction. In addition, gene expression 
profiles that are genotype dependent can be identified. GAGE uses fold changes for each gene 
to calculate mean and standard deviation of fold changes for a specific gene set (pathway), as 
well as for the whole transcriptome as a background, generating t-test statistics and a p-value 
for each gene set including the background in the respective comparison. Finally, to integrate 
and visualize enriched pathways, the Pathview R package was used to render the data 
(Gentleman et al., 2004). KEGG pathways that were identified as significantly differentially 
regulated were visualized using PathView, where upregulated genes are displayed in red and 
downregulated genes are in green and an unregulated gene in grey. The pathway is considered 
to be generally upregulated if the majority of genes are colored in red. A higher enrichment 
mean corresponds to a shifting of gene set constituents towards either end of the ranked list 
representing strongly upregulated or downregulated pathways.   
The differentially regulated pathways demonstrate that differentially expressed genes were 
mainly enriched in four main categories, which are (1) immune processes, (2) signal 
transduction, (3) cellular processes and (4) metabolism. The enrichment scores for both 
immune- and extracellular matrix remodeling-related pathways were significantly higher, 
while metabolism-related pathways had higher negative enrichment scores in both wild-type 
and STAT1-F77A after myocardial infarction. The top gene set enrichment analysis (GSEA)-









shown in Table 29 and Figure 13, and similarly for STAT1-F77A (LAD ligation vs sham) 
comparison in Table 30 and Figure 14, while Figure 15 lists both genotypes.  
 
Figure 13: List of KEGG differentially regulated pathways in wild-type mice post-MI.   
























mmu04060  Cytokine-cytokine receptor interaction  9.1 4.66e-18 1.03e-15 204 
mmu04062  Chemokine signalling pathway  5.2 1.70e-07 4.16e-06 167 
mmu04514  Cell adhesion molecules (CAMs)  4.5 4.80e-06 8.80e-05 117 
mmu04810  Regulation of actin cytoskeleton  4.3 9.56e-06 1.40e-04 195 
mmu04670  Leukocyte transendothelial migration  4.3 1.32e-05 1.82e-04 95 
mmu04510  Focal adhesion  2.3 1.03e-02 5.29e-02 192 
mmu04611  Platelet activation  2.1 1.66e-02 8.10e-02 116 
mmu04520  Adherens junction  2.1 1.91e-02 9.14e-02 70 
mmu04620  Toll-like receptor signalling pathway  4.7 2.93e-06 5.86e-05 85 
mmu04666  FcR-mediated phagocytosis  3.2 8.39e-04 6.84e-03 85 
mmu04640  Hematopoietic cell lineage  6.7 2.00e-10 2.20e-08 84 
mmu04659  Th17 cell differentiation  3.3 6.32e-04 5.56e-03 93 
mmu04657  IL-17 signalling pathway  6.1 4.73e-09 2.60e-07 78 
mmu04660  T cell receptor signalling pathway  3.3 5.44e-04 5.44e-03 93 
mmu04658  Th1 and Th2 cell differentiation  3 1.69e-03 1.32e-02 79 
mmu04662  B cell receptor signalling pathway  3.3 5.96e-04 5.56e-03 69 
mmu04650  Natural killer cell mediated cytotoxicity  4.8 1.93e-06 4.25e-05 96 
mmu04672  Intestinal immune network for IgA production  3.4 6.20e-04 5.56e-03 34 
mmu04610  Complement and coagulation cascades  3.5 3.91e-04 4.09e-03 59 
mmu04664  Fc epsilon RI signalling pathway  2.2 1.54e-02 7.69e-02 61 
















mmu04151  PI3K-Akt signalling pathway  3.2 7.66e-04 6.48e-03 306 
mmu04630  Jak-STAT signalling pathway  3.6 1.89e-04 2.18e-03 124 
mmu04668  TNF signalling pathway  5.6 4.48e-08 1.62e-06 108 
mmu04064  NF-B signalling pathway  5.6 5.15e-08 1.62e-06 89 
mmu04621  NOD-like receptor signalling pathway  5.4 7.44e-08 2.04e-06 146 
mmu04010  MAPK signalling pathway  4.3 8.88e-06 1.40e-04 272 
mmu04380  Osteoclast differentiation  6.4 4.91e-10 3.60e-08 122 
mmu04066  HIF-1 signalling pathway  2.9 2.25e-03 1.60e-02 95 
mmu04350  TGF- signalling pathway  2.7 3.95e-03 2.63e-02 73 
mmu04015  Rap1 signalling pathway  2.6 4.93e-03 3.03e-02 188 
mmu04622  RIG-I-like receptor signalling pathway  2.6 4.95e-03 3.03e-02 52 
mmu04390  Hippo signalling pathway  2.9 1.98e-03 1.45e-02 138 
mmu04115  p53 signalling pathway  2.4 8.59e-03 4.61e-02 69 













mmu04144  Endocytosis  2.7 3.74e-03 2.57e-02 240 
mmu04110  Cell cycle  2.6 4.95e-03 3.03e-02 119 
mmu04218  Cellular senescence  2.9 1.87e-03 1.42e-02 155 
mmu04210  Apoptosis  3.8 1.02e-04 1.24e-03 131 
mmu04217  Necroptosis  2.4 8.96e-03 4.69e-02 121 
mmu03010  Ribosome  2.5 6.99e-03 3.94e-02 130 
mmu04145  Phagosome  5.9 5.96e-09 2.62e-07 137 
mmu04146  Peroxisome  -4.5 8.56e-06 4.71e-04 78 
mmu03040  Spliceosome  2.5 6.16e-03 3.63e-02 127 
mmu04141  Protein processing in endoplasmic reticulum  2.5 6.26e-03 3.63e-02 155 
mmu04723  Retrograde endocannabinoid signalling  -3.2 6.97e-04 1.92e-02 122 










mmu00190  Oxidative phosphorylation  -6.3 1.28e-09 2.82e-07 116 
mmu00020  Citrate cycle (TCA cycle)  -3.9 1.84e-04 6.74e-03 30 
mmu01212  Fatty acid metabolism  -2.8 3.51e-03 7.72e-02 49 
mmu00071  Fatty acid degradation  -4 7.69e-05 3.39e-03 37 
mmu00640  Propanoate metabolism  -5.1 4.08e-06 4.49e-04 29 
mmu00310  Lysine degradation  -2.8 3.24e-03 7.72e-02 56 
mmu00380  Tryptophan metabolism  -2.7 4.39e-03 8.79e-02 33 
mmu00620  Pyruvate metabolism  -3.4 6.88e-04 1.92e-02 33 
mmu00280  Valine, leucine and isoleucine degradation  -4.6 7.44e-06 4.71e-04 47 










Figure 14: List of KEGG differentially regulated pathways following LAD ligation in transgenic 









Table 30: List of KEGG differentially regulated pathways following LAD ligation in STAT1-
F77A mice 














mmu04060  Cytokine-cytokine receptor interaction  8.7  6.39e-17  1.41e-14  204  
mmu04062  Chemokine signalling pathway  5.7  1.53e-08  5.60e-07  167  
mmu04514  Cell adhesion molecules (CAMs)  5.1  3.87e-07  8.51e-06  117  
mmu04810  Regulation of actin cytoskeleton  4.2  2.03e-05  3.19e-04  195  
mmu04670  Leukocyte transendothelial migration  4.1  2.71e-05  3.97e-04  95  
mmu04510  Focal adhesion  2.5  6.26e-03  3.53e-02  192  
mmu04611  Platelet activation  2.2  1.40e-02  7.18e-02  116  
mmu04520  Adherens junction  2.2  1.48e-02  7.40e-02  70  
mmu04620  Toll-like receptor signalling pathway  4.6  4.14e-06  7.60e-05  85  
mmu04666  FcR-mediated phagocytosis  3.2  7.22e-04  6.62e-03  85  
mmu04640  Hematopoietic cell lineage  6.2  2.89e-09  1.59e-07  84  
mmu04659  Th17 cell differentiation  3.3  5.96e-04  5.70e-03  93  
mmu04657  IL-17 signalling pathway  6.1  5.81e-09  2.56e-07  78  
mmu04660  T cell receptor signalling pathway  3.4  3.77e-04  3.77e-03  93  
mmu04658  Th1 and Th2 cell differentiation  3  1.43e-03  1.17e-02  79  
mmu04662  B cell receptor signalling pathway  3  1.70e-03  1.29e-02  69  
mmu04650  Natural killer cell mediated cytotoxicity  4.4  8.80e-06  1.49e-04  96  
mmu04672  Intestinal immune network for IgA production  3.6  2.95e-04  3.09e-03  34  
mmu04610  Complement and coagulation cascades  3  1.69e-03  1.29e-02  59  
















mmu04151  PI3K-Akt signalling pathway  3.1  1.02e-03  8.96e-03  306  
mmu04630  Jak-STAT signalling pathway  3.5  2.76e-04  3.06e-03  124  
mmu04668  TNF signalling pathway  5.5  5.72e-08  1.40e-06  108  
mmu04064  NF-B signalling pathway  5.6  3.62e-08  1.14e-06  89  
mmu04621  NOD-like receptor signalling pathway  5.5  4.48e-08  1.23e-06  146  
mmu04010  MAPK signalling pathway  3.9  4.86e-05  6.69e-04  272  
mmu04380  Osteoclast differentiation  6.3  8.57e-10  9.43e-08  122  
mmu04066  HIF-1 signalling pathway  2.7  4.22e-03  2.66e-02  95  
mmu04350  TGF- signalling pathway  2.6  5.50e-03  3.36e-02  73  
mmu04015  Rap1 signalling pathway  2.8  2.32e-03  1.60e-02  188  
mmu04622  RIG-I-like receptor signalling pathway  2.8  3.34e-03  2.22e-02  52  
mmu04390  Hippo signalling pathway  2.3  1.14e-02  6.13e-02  138  
mmu04115  p53 signalling pathway  2.5  7.40e-03  4.07e-02  69  
mmu04623  Cytosolic DNA-sensing pathway  3.9  1.05e-04  1.28e-03  46  












mmu04144  Endocytosis  2.9  2.05e-03  1.50e-02  240  
mmu04110  Cell cycle  2.9  2.24e-03  1.59e-02  119  
mmu04260  Cardiac muscle contraction  -3.3  5.57e-04  1.36e-02  67  
mmu04218  Cellular senescence  3  1.40e-03  1.17e-02  155  
mmu04210  Apoptosis  3.5  2.79e-04  3.06e-03  131  
mmu04217  Necroptosis  2.2  1.52e-02  7.44e-02  121  
mmu04145  Phagosome  6.1  2.03e-09  1.49e-07  137  
mmu04146  Peroxisome  -4.5  5.53e-06  2.44e-04  78  
mmu03040  Spliceosome  2.5  5.88e-03  3.40e-02  127  
mmu04141  Protein processing in endoplasmic reticulum  2.5  5.83e-03  3.40e-02  155  
mmu04723  Retrograde endocannabinoid signalling  -3.6  2.02e-04  5.56e-03  122  










mmu00190  Oxidative phosphorylation  -8.1  3.66e-14  8.06e-12  116  
mmu00020  Citrate cycle (TCA cycle)  -5.1  3.38e-06  1.86e-04  30  
mmu01212  Fatty acid metabolism  -2.8  3.56e-03  6.02e-02  49  
mmu00071  Fatty acid degradation  -4.1  5.31e-05  1.67e-03  37  
mmu00640  Propanoate metabolism  -5.8  3.59e-07  2.63e-05  29  
mmu00380  Tryptophan metabolism  -3  2.01e-03  4.01e-02  33  
mmu00620  Pyruvate metabolism  -4.2  4.22e-05  1.55e-03  33  
mmu00280  Valine, leucine and isoleucine degradation  -5.4  2.58e-07  2.63e-05  47  
mmu00532  Glycosaminoglycan biosynthesis  2.8  4.19e-03  2.66e-02  20  
mmu00650  Butanoate metabolism  -2.8  4.39e-03  6.90e-02  19  
mmu00630  Glyoxylate and dicarboxylate metabolism  -2.7  5.15e-03  7.55e-02  28  
mmu01200  Carbon metabolism  -2.9  1.98e-03  4.01e-02  106  
mmu00982  Drug metabolism - cytochrome P450  -2.8  3.12e-03  5.72e-02  37  









mmu00980  Metabolism of xenobiotics by cytochrome P450  -2.6  6.31e-03  8.16e-02  39  
 
 









3.6 Identification of immune-related pathways differentially regulated after myocardial 
infarction   
In this study, KEGG pathways that were classified as immune processes significantly 
enriched post-myocardial infarction in both wild-type and STAT1-F77A mice were the 
following: cytokine-cytokine receptor interaction (Figure 17), chemokine signalling pathway 
(Figure 18), cell adhesion molecules (CAMs) (Figure 19), regulation of actin cytoskeleton 
(Figure 20), leukocyte transendothelial migration (Figure 21), focal adhesion, platelet 
activation, adherens junction, Toll-like receptor signalling pathway, FcR-mediated 
phagocytosis, hematopoietic cell lineage, Th17 cell differentiation, IL-17 signalling pathway, 
T cell receptor signalling pathway, Th1 and Th2 cell differentiation, B cell receptor signalling 
pathway, natural killer cell-mediated cytotoxicity, intestinal immune network for IgA 
production, complement and coagulation cascades, Fc epsilon RI signalling pathway, and 
antigen processing and presentation.  
 
 
Figure 16: List of KEGG immune responses that were differentially regulated in both STAT1-













Figure 17: Pathview of the “cytokine-cytokine receptor interaction” KEGG pathway in wild-













Figure 18: Pathview of the “chemokine signalling” KEGG pathway in wild-type and STAT1-









WT         
 STAT1-F77A 
 
Figure 19: Pathview of the “cell adhesion molecules (CAMs)” KEGG pathway in the two STAT1 














Figure 20: Pathview of the “regulation of actin cytoskeleton” KEGG pathway in mice with with 














Figure 21: Pathview of the “leukocyte transendothelial migration” KEGG pathway in the two 











3.7 Identification of signal pathways and cellular processes differentially regulated after 
LAD ligation   
Since signal transduction pathways transmit extracellular stimuli inside the cell thereby 
regulating the expression of genes with important physiological functions, we performed 
differential expression analysis to identify the most significantly enriched signal pathways. 
Signal transduction pathways that were associated with myocardial infarction and were 
genotype-independent are the following: PI3K-Akt signalling (Figure 23), JAK-STAT 
signalling (Figure 24), TNF signalling (Figure 25), NF-B signalling (Figure 26), NOD-like 
receptor signalling (Figure 27), MAPK signalling, osteoclast differentiation, HIF-1 signalling, 
TGF- signalling, Rap1 signalling, RIG-I-like receptor signalling, Hippo signalling, p53 




Figure 22: List of KEGG immune responses and signal transduction pathways that are 













Figure 23: Pathview of the “PI3K-Akt signalling” KEGG pathway in wild-type and STAT1-














Figure 24: Pathview of the “Jak-STAT signalling” KEGG pathway in wild-type and STAT1-













Figure 25: Pathview of the “TNF signalling” KEGG pathway in wild-type and STAT1-F77A 













Figure 26: Differential expression of components in the “NF-B signalling” KEGG pathway in 















Figure 27: Pathview of the “NOD-like receptor signalling” KEGG pathway in wild-type and 









Additionally, the top significantly perturbed cellular processes associated with MI which are 
genotype-independent include: endocytosis (Figure 29), cell cycle (Figure 30), cellular 
senescence (Figure 31), apoptosis (Figure 32), necroptosis (Figure 33), phagosome, 
peroxisome, spliceosome, protein processing in endoplasmic reticulum, and retrograde 
endocannabinoid signalling and ribosome biogenesis in eukaryotes. Interestingly, we found 
cardiac muscle contraction to be uniquely differentially regulated in STAT1-F77A (MI vs 
sham) comparison only (q-value=1.36x10-2), while ribosome pathway was significantly 
differentially regulated in wild-type (MI vs sham) comparison only (q-value=3.94 x10-2). 
 
Figure 28: List of KEGG differentially regulated cellular processes following LAD ligation in 
wild-type and STAT1-F77A mice. Upregulated pathways are displayed in red and 
downregulated pathways are in green. *Cardiac muscle contraction is uniquely differentially 
regulated in STAT1-F77A (MI vs sham) comparison only, while ribosome pathway is 




























Figure 30: Pathview of the “cell cycle” KEGG pathway in wild-type and STAT1-F77A mice 












Figure 31: Pathview of the “cellular senescence” KEGG pathway in wild-type and STAT1-F77A 












Figure 32: Pathview of the “apoptosis” KEGG pathway in wild-type and STAT1-F77A mice 













Figure 33: Pathview of the “necroptosis” KEGG pathway in mice expreesing wild-type STAT1 










3.8 Gene set enrichment analysis revealed changes in metabolic signature following 
myocardial infarction  
The heart has the capacity to metabolize various types of substrates to synthesize ATP. In this 
study, we observed that both processes of energy production and energy utilization are 
dysregulated in the failing heart. Differential analysis revealed downregulation of metabolic 
pathways, involving oxidative phosphorylation (Figure 34), citrate cycle (TCA cycle) (Figure 
35), fatty acid metabolism (Figure 36), fatty acid degradation (Figure 37), propanoate 
metabolism (Figure 38), tryptophan metabolism, pyruvate metabolism, valine, leucine and 
isoleucine degradation and glycosaminoglycan biosynthesis in both wild-type and STAT1-
F77A following myocardial infarction. Whereas lysine degradation was only significantly 
differentially regulated in wild-type (MI vs sham) comparison, other pathways significantly 
differentially regulated in STAT1-F77A (MI vs sham) were butanoate metabolism, glyoxylate 
and dicarboxylate metabolism, carbon metabolism, drug metabolism-cytochrome P450, 
PPAR signalling pathway, and metabolism of xenobiotics by cytochrome P450. Similarly, 
performing hierarchical clustering analysis showed that the 1428 DEGs which are 
downregulated in STAT1-F77A have similar functions, which are involved in the regulation 
of metabolic pathways related to oxidative phosphorylation, citrate cycle (TCA cycle), fatty 
acid metabolism, fatty acid degradation, propanoate and tryptophan metabolism, pyruvate 
metabolism, and valine, leucine and isoleucine degradation. In addition, those genes were 
associated with glycosaminoglycan biosynthesis, butanoate metabolism, glyoxylate and 
dicarboxylate metabolism, carbon metabolism, drug metabolism and cytochrome P450, and 
PPAR signalling pathway (Figure 39). From these data, we hypothesize that the differential 
gene expression pattern between animals from the two genotypes resulted from a higher 
immune cell infiltration in STAT1-F77A mice, demonstrating a metabolic shift from 



















Figure 34: Pathview of the “oxidative phosphorylation” KEGG pathway in wild-type and 













Figure 35: Pathview of the “citrate cycle (TCA cycle)” KEGG pathway in wild-type and STAT1-














Figure 36: Pathview of the “fatty acid metabolism” KEGG pathway in wild-type and STAT1-














Figure 37: Pathview of the “fatty acid degradation” KEGG pathway in wild-type and STAT1-












Figure 38: Pathview of the “propanoate metabolism” KEGG pathway in wild-type and STAT1-











            
 






Figure 39: Gene set enrichment analysis of differentially downregulated genes in STAT1-F77A 
post-MI.  
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3.9 Differentially regulated pathways in F77A as compared to wild-type mice in the 
infracted area following LAD ligation 
Using KEGG pathway enrichment analysis, 18 KEGG pathways were identified when 
comparing STAT1-F77A and wild-type mice post-LAD ligation, among which oxidative 
phosphorylation, cardiac muscle contraction, citrate cycle were observed to be the top three in 
mean enrichment score (Figure 40). Table 31 below illustrates the KEGG pathway ID, KEGG 
name, mean enrichment score, p-value, q-value, and the number of genes in each respective 
pathway comparing STAT1-F77A and wild-type mice post-MI. Furthermore, gene set 
enrichment analysis revealed differential expression of cardiac muscle contraction pathway 
only in STAT1-F77A mice at day 1 post-MI (Figure 41).  
 
 
Table 31: List of KEGG differentially regulated pathways comparing STAT1-F77A and wild-
type mice post-MI. 
KEGG ID KEGG pathway mean p-value q-value size 
mmu00190 Oxidative phosphorylation -8.2 1.48e-14 3.26e-12 116 
mmu04260 Cardiac muscle contraction -4.9 1.33e-06 1.46e-04 67 
mmu00020 Citrate cycle (TCA cycle) -4.1 7.43e-05 5.45e-03 30 
mmu00280 Valine, leucine and isoleucine degradation -3.8 1.36e-04 6.53e-03 47 
mmu00640 Propanoate metabolism -3.9 1.48e-04 6.53e-03 29 
mmu04621 NOD-like receptor signalling pathway 4 3.46e-05 7.61e-03 146 
mmu04723 Retrograde endocannabinoid signalling -3.5 3.08e-04 1.13e-02 122 
mmu03008 Ribosome biogenesis in eukaryotes 3.4 5.00e-04 3.86e-02 72 
mmu04380 Osteoclast differentiation 3.3 5.26e-04 3.86e-02 122 
mmu00620 Pyruvate metabolism -3.1 1.34e-03 4.22e-02 33 
mmu04657 IL-17 signalling pathway 3 1.60e-03 6.46e-02 78 
mmu04144 Endocytosis 3 1.65e-03 6.46e-02 240 
mmu04668 TNF signalling pathway 2.9 1.85e-03 6.46e-02 108 
mmu04060 Cytokine-cytokine receptor interaction 2.8 2.43e-03 6.46e-02 204 
mmu03013 RNA transport 2.8 2.46e-03 6.46e-02 150 
mmu04062 Chemokine signalling pathway 2.8 2.64e-03 6.46e-02 167 
mmu01200 Carbon metabolism -2.8 3.11e-03 8.56e-02 106 















Figure 40: List of KEGG differentially regulated pathways comparing STAT1-F77A MI and 











Figure 41: Pathview of the “cardiac muscle contraction” KEGG pathway in STAT1-
F77A following LAD ligation. 
 
3.10 A gene expression signature indicative of immune cells infiltration detected in F77A 
mice following LAD ligation 
Recent studies have demonstrated the prognostic and predictive roles of immune markers in 
several inflammatory diseases. Nevertheless, additional characterization of these markers in 
the context of myocardial infarction is evidently warranted. We aimed at identifying putative 
target genes that are differentially regulated in STAT1-F77A as compared to wild-type. A list 
of immune markers signifying an immunologically active microenvironment was identified in 













Figure 42: Gene expression signature associated with immune infiltration at day-1 post-MI in 
STAT1-F77A as compared to wild-type. Each point indicates a gene-of-interest that displays both 
large magnitude fold-changes (x-axis) as well as high statistical significance (−log10 of p-value, y-
axis) in STAT1-F77A comparison as compared to wild-type. The horizontal dashed line shows the p-
value cutoff. The vertical dashed lines show 2-fold change cutoff. Therefore, genes that are highly 
dysregulated are further to the left and right sides, while highly significant changes appear higher on 
the plot. 
 
These markers can be categorized into immune-activating chemokines and their receptors 
(e.g. Ccl2, Ccl22, Ccr1, Cxcl10, Cxcl2, Cxcl3, and Cxcr2), adhesion molecules (e.g. S100A8, 
S100A9, Sell, Selp, Thbs1, Tnc, and Mmp9), cytokines and their receptors (e.g. Cd14, Csf2rb, 
Csf3r, Fpr1, Il18rap, Il1b, Il1f9, Il1r2, Il1rn, Il6, Inhba, Tnfrsf9, Tnfsf14, Lilrb4, Mefv, Osm), 
growth factors and their receptors (e.g. Ereg, Fgf23), coagulation cascade proteins (e.g. F10), 
and heat shock proteins (e.g. Hspa1a, Hspa1b). These data suggest a significant upregulation 
of both CC and CXC chemokine transcripts in the early period of acute MI, which can play a 
critical role in repair processes and as a hallmark of the inflammatory response following 
LAD ligation. Higher expression levels of these chemokines and their receptors and 
consequently chemokine-receptor interactions may affect immune cell activation and 
trafficking in the infarcted area of STAT1-F77A mice. The magnitude of remodeling is 
affected by the chemokine signals involved in the reparative process and the sequential 
recruitment of immune cell subpopulations that are pro-inflammatory or regulatory to the 











Table 32: Genes associated with immune cells activation at day 1 following LAD ligation in 
STAT1-F77A 
Gene log2 fold change log10 padj  KEGG pathway  
Ccl2  3.08  1.34e+01  Chemokine signalling pathway  
Ccl22  3.31  1.17e+01  Chemokine signalling pathway  
Ccr1  3.38  1.40e+01  Chemokine signalling pathway  
Cd14  2.97  1.14e+01  MAPK signalling pathway  
Csf2rb  3.26  1.38e+01  Jak-STAT signalling pathway  
Csf3r  3.62  1.48e+01  PI3K-Akt signalling pathway  
Cxcl10  3.76  1.23e+01  RIG-I-like receptor signalling pathway  
Cxcl2  4.51  1.79e+01  Chemokine signalling pathway  
Cxcl3  4.76  1.90e+01  Chemokine signalling pathway  
Cxcr2  4.19  1.75e+01  Endocytosis  
Ereg  3.71  1.18e+01  PI3K-Akt signalling pathway  
F10  3.69  1.36e+01  Complement and coagulation cascades  
Fgf23  4.89  1.89e+01  Ras signalling pathway  
Fpr1  3.88  1.59e+01  Rap1 signalling pathway  
H2-Q10  3.69  1.37e+01  Endocytosis  
Hspa1a  4.12  1.33e+01  Protein processing in endoplasmic reticulum  
Hspa1b  3.94  1.20e+01  Protein processing in endoplasmic reticulum  
Il18rap  3.29  1.26e+01  Cytokine-cytokine receptor interaction  
Il1b  3.89  1.66e+01  Necroptosis  
Il1f9  3.90  1.65e+01  Cytokine-cytokine receptor interaction  
Il1r2  4.41  1.66e+01  Hematopoietic cell lineage  
Il1rn  3.67  1.35e+01  Cytokine-cytokine receptor interaction  
Il6  4.09  1.49e+01  HIF-1 signalling pathway  
Inhba  3.87  1.24e+01  TGF- signalling pathway  
Lilrb4  2.90  1.16e+01  Osteoclast differentiation  
Mefv  3.72  1.33e+01  NOD-like receptor signalling pathway  
Mmp9  3.82  1.57e+01  Leukocyte transendothelial migration  
Oas3  3.55  1.22e+01  NOD-like receptor signalling pathway  
Osm  3.96  1.44e+01  PI3K-Akt signalling pathway  
Plaur  3.69  1.42e+01  Complement and coagulation cascades  
Ptgs2  4.27  1.46e+01  NF-B signalling pathway  
S100a8  3.66  1.75e+01  IL-17 signalling pathway  
S100a9  3.79  1.72e+01  IL-17 signalling pathway  
Sell  3.44  1.45e+01  Cell adhesion molecules (CAMs)  









Serpine1  3.66  1.21e+01  p53 signalling pathway  
Thbs1  3.82  1.58e+01  Focal adhesion  
Timp1  2.89  1.14e+01  HIF-1 signalling pathway  
Tnc  3.66  1.34e+01  Focal adhesion  
Tnfrsf9  3.95  1.16e+01  Cytokine-cytokine receptor interaction  
Tnfsf14  3.57  1.26e+01  NF-B signalling pathway  











3.11 Analysis of STAT1-target genes associated with myocardial infarction 
Since a perturbation in STAT1-target gene networks is linked to multiple autoimmune 
diseases and tumorigenesis, it is noteworthy to investigate the global transcriptional network 
of STAT1-target genes after myocardial infarction (Cao et al., 2017). Using a list of 1,441 
ChIP-Seq-based STAT1 target genes in IFN-γ-treated HeLa cells published by Satoh and 
Tabunoki (2013), we constructed a functional protein association network of 132 STAT1-
target genes that are differentially regulated in wild-type mice (Figure 43) and another protein 
association network of 180 STAT1-target genes differentially regulated in STAT1-F77A 
(Figure 44) at day 1 following myocardial infarction. A fold change >1 was used as a cut-off 
value. 
 
Figure 43: A functional protein association network of 132 STAT1 target genes differentially 










Figure 44: A functional protein association network of 180 STAT1 target genes differentially 
regulated in F77A post-MI.  
 
3.12 Co-stimulatory effects of interferon-, interferon-, and interleukin-6 in MHEC-5 
cells 
Intriguingly, STAT1-target genes appear to promote inflammation and antagonize 
proliferation. This contrasts the pro-proliferative and anti-inflammatory activities associated 
with STAT3, which raises the possibility of balancing the activation of both STAT1 and 
STAT3 by members of the IFN and IL-6 families. To identify the transcriptional outcome that 
is induced by activated STAT proteins, we used a murine myocardium-derived endothelial 
cell line (MHEC-5) to study the phosphorylation levels and the protein expression levels of 
STAT1 and STAT3 following 45 min stimulation with IFN-, IFN-γ, IL-6, or any 
combination thereof. We found that co-stimulation with IL-6 and IFN-γ reduced the RNA 









cells compared to cells treated with IFN-γ only (Figure 45A), whereas co-stimulation with IL-
6 and IFN-γ did not alter the level of STAT1 tyrosine phosphorylation in comparison to cells 

















Figure 45: Co-stimulatory effects of interferon-, interferon-, and interleukin-6 in MHEC-5 
cells on (A) the induction of STAT1 target gens and (2) the expression and phosphorylation 











3.13 Generation of STAT1- and STAT3-knockdown HL-60 cell lines  
In addition to acting as cytoskeletal proteins, the ezrin, radixin and moesin (ERM)  proteins 
act as signaling adaptors and play a fundamental role regulating invasion and cellular cortical 
tension, both of which are required for efficient transendothelial migration. Given the 
complex phenotype presented in the STAT1-F77A mice challenged with MI, STAT1 and 
STAT3 were systematically knocked down as a proof of concept study to determine if 
reducing STAT1 expression in neutrophils would interfere with recruitment and 
transendothelial migration. Lentiviral vectors with short hairpin RNA (shRNA) were used to 
transfect the human leukemia cell line HL-60. Immunoblotting was utilized to assess the 
relative protein levels in STAT1 and STAT3 shRNA-transfected cells compared to cells 
transfected with control shRNA. Total STAT1 levels were reduced following transfection 
with 3 different anti-STAT1 shRNA, whereas total STAT3 levels were reduced using 5 
different anti-STAT3 shRNA viral clones, as can be seen in Figure 46. HL-60 cells that are 
transfected with lentiviral shSTAT1 clone#3 and HL-60 cells transfected with shSTA3 
clone#5 were used in the following experiments, as they have shown the highest percentage 
of knockdown according to the ratios of STAT1 and STAT3 proteins to -actin in each lane 
in comparison to shRNA control. 
 
 









3.14 DMSO-induced differentiation results in upregulation of STAT1 and STAT3 in 
HL-60 cells 
In order to further characterize the mechanisms involved in HL-60 cells differentiation, we 
examined the kinetics of STAT1 and STAT3 expression in response to 1.3% DMSO 
stimulation. Protein extracts were collected at days 0, 1, 2, 3, 4, and 5 and were subjected to 
immunoblot analyses. DMSO stimulation led to the induction of STAT1 and STAT3 
expression, where the peak of STAT1 expression was at day 4, and the peak of STAT3 
expression was at day 5 in STAT1 and STAT3-knockdown cells, respectively (Figure 47). 
These data suggest that STATs signalling is involved in the differentiation of HL-60 cells.  
 
 
Figure 47: STAT1 and STAT3 expression levels in control as well as STAT1- and STAT3-
knockdown HL-60 cells differentiated with DMSO 
 
3.15 Decreased phosphorylation levels of STAT1 and STAT3 in HL-60 knockdown cells 
To further characterize the generated STAT1- and STAT3-knockdown cells, we differentiated 
HL-60 cells with 1.3% DMSO and analyzed them at day 4 for the phosphorylation levels of 









(10 ng/ml) or both IFN- and IL-6 for 6 and 24 hours. Our results show that STAT1 
phosphorylation levels upon stimulation with IFN- or both IFN- and IL-6 are significantly 
increased, whereas STAT3 phosphorylation is induced in IFN-, IL-6 or both IFN- and IL-6 
stimulation conditions as compared to unstimulated cells. Additionally, STAT1 and STAT3 
phosphorylation levels are significantly decreased in STAT1-knockdown and STAT3-
knockdown HL-60 cells, respectively, as compared to control shRNA transfected cells. 
Moreover, immunoblots of STAT1 and STAT3 demonstrated that downregulation of STAT1 
in HL-60 cells by shRNA expression had no effect on STAT3 expression level. However, the 
knockdown of STAT3 in HL-60 cells by shRNA had a negative effect on the expression 
levels of STAT1. Furthermore, the phosphorylation levels of STAT1 were reduced in 




Figure 48: STAT1 expression levels and phosphorylation in HL-60 cells differentiated with 













Figure 49: STAT1 and STAT3 expression and phosphorylation in control, shSTAT1, and 
shSTAT3 HL-60 cells differentiated with DMSO. Stimulation was performed with IFN-, IL-6 or 

















































































































3.16 Downregulation of ezrin in STAT1- and STAT3-knockdown HL-60 cells  
Ezrin, a member of the ezrin/radixin/moesin (ERM) family of proteins, cross-links the 
cytoskeleton and the cell membrane mediating various cellular processes. Here, to investigate 
the expression of ezrin, we blotted for ezrin in control and STAT1 and STAT3-knockdown 
HL-60 cells that are differentiated with DMSO (day 4). In this preliminary data we found that 
the knockdown of STAT1 and STAT3 by shRNA decreased the expression of ezrin in HL-60 
cells when left untreated or treated with IFN- and IL-6 or a combination of both for 24 




Figure 50: Ezrin expression levels in control, STAT1- and STAT3-knockdown HL-60 cells 
differentiated with 1.3% DMSO. Cells were analyzed at day 4 and left unstimulated or stimulated 
with IFN-, IL-6 or combination of both for 24 hours. 
3.17 Reduced transendothelial migration in HL-60 cells with decreased STAT1 and 
STAT3 expression  
Parallel plate flow chamber assays were used for live-cell imaging to investigate the role of 
STAT1 and STAT3 on the recruitment and transmigration of neutrophil-like HL-60 cells to 
activated endothelial monolayers under constant flow conditions. While tracking of 
transmigrating cells have shown a reduced transendothelial migration in both STAT1 and 
STAT3-knockdown HL-60 cells, STAT3-knockdown resulted in a more pronounced 
inhibition of transmigration across the HUVEC endothelial monolayer as compared to control 
cells (n=3) (Figure 51). Interestingly, STAT3 knockdown has further impacted cell polarity 




































Figure 51: Extravasation analysis of HL-60 cells across HUVEC monolayer in STAT1 and 
STAT3 shRNA-transfected cells compared to cells transfected with control shRNA. All cells were 












4. Discussion  
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling 
pathway has been identified as a critical regulator of several physiological responses 
following cardiac insult including oxidative damage, myocarditis, and cardiac hypertrophy. 
Moreover, elevated levels of circulating cytokines have been recognized to activate the JAK-
STAT signal transduction and modulate the functional status of heart patients (Rumalla et al., 
2002; Jug et al., 2009; Parissis et al., 2004; Ruppert and Meyer, 2007; Simon et al., 1998; 
Ueland et al., 2015; Wagner and Siddiqui, 2012). 
Interferon signalling is initiated by binding of the cytokine to the extracellular domain of its 
cognate receptor. To facilitate differential regulation of type I and type II interferon 
signalling, interferon- receptor recruits STAT1 as well as STAT2, while interferon- 
receptor exclusively recruits STAT1. The STAT1 homodimer is formed by interactions 
between the SH2 domains of two phosphorylated STAT1 protomers. The STAT1-F77A point 
mutant, with alanine substituted for phenylalanine at position 77, is defective in forming 
stabilized tetramers on DNA and shows no cooperative DNA binding (Begitt et al., 2014).  
In this project, the role of STAT1-cooperative DNA binding, its transcriptional consequences 
in the infarcted myocardium, and its impact on cardiac function have been investigated in a 
mouse model of tetramerisation-deficient STAT1 signalling. To this end, permanent 
occlusion of the left anterior descending coronary artery was performed to experimentally 
induce infarction in the left ventricle in wild-type and knock-in STAT1-F77A mice, whereas 
sham-operated mice were used as controls to determine baseline characteristics.  
To assess cardiac structure and function following sham operation and LAD ligation, we 
analyzed cardiac chamber dimensions, fractional shortening, intracardial volumes, the 
ejection fraction, and wall thickness using echocardiographic ultrasound imaging with two 
dimensional views of the heart (short and long axis). Subsequently, RNA-seq technology was 
used to delineate the role of STAT1-cooperative DNA binding by analyzing RNA samples 
from the infarcted tissue in wild-type and knock-in mice in comparison to sham-operated left 
ventricular myocardium (Wang et al., 2009).  
Assessment of echocardiographic parameters in wild-type and STAT1-F77A mice 
demonstrated a crucial role of STAT1 signalling, where IFN-γ-irresponsive female mice 
lacking cooperative DNA binding were protected from adverse cardiac remodeling (Figure 4). 
This finding is consistent with previous observations, in which mice deficient in interferon 
regulatory factor 3 (IRF3) or type I IFN receptor (IFNAR) have an improved survival rate 
 
 






following MI as compared to control mice (King et al., 2017). In the same study, single-cell 
RNA-seq analysis of 4215 isolated leukocytes from infarcted and healthy heart tissues 
revealed an activation of the IRF3-interferon axis in cardiac macrophages which had driven a 
fatal response.  
Moreover, treatment of mice with an IFNAR-neutralizing antibody post-MI abrogated the 
interferon response and improved left ventricular size, contractile function, and survival 
(King et al., 2017). Similar results were also reported in another study, in which STAT1-
deficient mice had a significantly smaller infarct size compared to wild-type mice. The 
authors observed an upregulation of autophagy in STAT1-deficient hearts, characterized by 
light chain 3 (LC3)-I/LC3-II conversion and an increased expression of cellular autophagy 
markers Atg12 and Beclin 1, suggesting that the absence of functional STAT1 signalling is 
protective within the context of myocardial infarction by enhancing autophagy (McCormick 
et al., 2012).   
It has been previously reported that STAT1 activates Fas/FasL genes and apoptosis in cardiac 
myocytes, when subjected to ischemia/reperfusion injury, which was mediated by the 
phosphorylation of serine residue 727, but not the tyrosine residue 701 of STAT1 (Stephanou 
et al., 2001). Further in vitro experiments have shown that STAT1 interacts directly with p53 
to regulate the expression of pro-apoptotic target genes, such as Bax, Noxa, and Fas. These 
data provide further support for the role of STAT1 in promoting DNA damage-induced 
apoptosis (Townsend et al., 2004). Similarly, a previous study by Stephanou and co-workers 
demonstrated a higher susceptibility to ischemia-induced cell death in STAT1-transfected 
cells compared to cells transfected with control plasmid. The authors have also reported an 
activation of STAT1 and caspase-1 processing in myocytes following ischemia/reperfusion 
injury using an ex vivo model of intact heart (Stephanou et al., 2000). Over the last decade, 
the literature has further accumulated enough data to convincingly establish a role for the 
JAK/STAT signalling pathway in ischemia-reperfusion injury and ischemic post-conditioning 
(Barry et al., 2007; Boengler et al., 2010; Dawn et al., 2004; Goodman et al., 2008; Goodman 
et al., 2011; Gross et al., 2006; Heusch et al., 2012; Huffman et al., 2008; Kodama et al., 
1998; Smith et al., 2010; Xuan et al., 2005). Of particular importance are the experiments by 
several groups concerning the cardioprotective effects of STAT3 during ischemia/reperfusion 
injury as well as under pressure overload (Bolli et al., 2011; Butler et al., 2006; Fuglesteg et 
al., 2008; Heusch et al., 2011; Hilfiker-Kleiner et al., 2004; Jacoby et al., 2003; Kunisada et 










Numerous studies in this fast-moving field have now convincingly shown that abrupt 
reduction in blood flow through the coronary artery can expose the cells to hypoxia, resulting 
in an irreversible cell damage and necrosis (Semenza et al., 2014). Necrosis, characterized by 
cytoplasmic granulation and cellular swelling, leads to cell membrane rupture and breakdown 
of organelles, which consequently culminates in the activation of a severe inflammatory 
response (Kung et al., 2011). However, the mechanisms of how STAT1 cooperative DNA 
binding plays a role in mediating this MI-associated inflammatory response have remained 
unexplored.  
In this study, next-generation sequencing (RNA-seq) technology was used to analyze the 
transcriptome of infarcted tissue in STAT1-F77A mice as compared to wild-type littermates. 
This approach has gained high-resolution data without any previous knowledge about the 
sequences under exploration. Within the ongoing efforts to construct a comprehensive model 
which can predict phenotypes from the transcriptomic data, KEGG (Kyoto Encyclopedia of 
Genes and Genomes) tries to answer different biological questions by integrating the recent 
understanding of molecular functions and processes at the level of genes, proteins, and 
pathways (Kanehisa and Goto, 2000).  
Interestingly, our gene set enrichment analysis has revealed PI3K-Akt and JAK-STAT 
signalling pathways as the top enriched signal transduction pathways following myocardial 
infarction. A previous study has demonstrated that the activation of PI3K (p110 ) in mice 
protects against myocardial infarction-induced heart failure (Lin et al., 2010). In our data set, 
transcriptomic analysis of cardiac tissue at day 1 following myocardial infarction revealed 
prominent gene expression changes in wild-type mice and STAT1 tetramerisation-deficient 
mice. We observed a significantly higher number of differentially expressed genes in STAT1-
F77A mice, since 2337 genes were differentially regulated with a |log2(fold change)| >1 and a 
p-value < 0.05, including 909 upregulated genes and 1428 downregulated genes compared to 
wild-type mice (Figure 8).  
Utilizing KEGG database, we have identified common and unique differentially expressed 
pathways in both wild-type and STAT1-F77A animals following LAD ligation. These were 
enriched in four categories including immune processes, signal transduction, cellular 
processes, and metabolism (Figure 13 and Figure 14). The top enriched immune processes 
that are upregulated post-MI in both wild-type and knock-in mice are cytokine-cytokine 
receptor interactions, chemokine signalling pathways, cell adhesion molecules, regulation of 
actin cytoskeleton, and leukocyte transendothelial migration.  
 
 






These data are in line with prior studies where gene expression data sets of MI patients were 
analyzed. For instance, Kontou et al. has identified using blood samples of 93 MI patients and 
89 healthy controls differentially expressed genes involved in inflammation, wound healing, 
nuclear pore proteins, and RNA processing and transport (Kontou et al., 2018). In patients 
with ST-elevation myocardial infarction (STEMI), Muller and colleagues have used custom-
designed DNA array to analyze blood samples at the site of occlusion and in the peripheral 
circulation during primary percutaneous coronary intervention. Validation of identified genes 
by qPCR has demonstrated an upregulation of chemokines (Ccl2, Ccl18 and Cxcl12), cell-
extracellular matrix (Fn1, Cdh5 and Spp1), and lipoprotein modification genes (Apoe) in local 
versus peripheral blood (Muller et al., 2011).  
Moreover, current research has shown that low serum levels of CCL2 chemokine 
(≤100.9 pg/mL) in 803 patients with acute coronary syndrome were significantly associated 
with fatal and non-fatal myocardial infarction (Leocádio et al., 2019). Using microarray and 
protein networks to analyze blood samples from 127 acute MI patients, Devaux and co-
workers have demonstrated the involvement of vascular endothelial growth factor B (Vegf-b), 
thrombospondin-1 (Thbs1) and placental growth factor (Pgf) as potential biomarkers (Devaux 
et al., 2010). In addition, using RNA-seq of MI patients’ blood samples, Zhao and colleagues 
have identified several immune-related genes, including interferon-induced protein with 
tetratricopeptide repeats 3 (Ifit3), interferon-induced GTP-binding protein (Mx1), and major 
histocompatibility complex class II DQ  1 (Hla-dqa1) as potentially relevant for myocardial 
infarction (Zhao et al., 2018).  
In a recently published study in mice, several pro-inflammatory transcripts have been 
detected during the first week post-myocardial infarction, including tumor necrosis factor-α 
(Tnf-α), monocyte chemoattractant protein-1 (Mcp-1), interleukin-6 (Il-6), and interleukin-1β 
(Il1-β). Administration of an TNF-α inhibitor has been reported to adversely affect cardiac 
function, suggesting that inflammatory responses play a protective role in the early stage of 
myocardial infarction (Wang et al., 2018). Furthermore, recent research has shown in mice 
that depleting neutrophils from the infarcted myocardium at day 1, using a monoclonal anti-
Gr-1 antibody, had resulted in a downregulation of IFN-γ and TNF-α mRNA transcripts, 
higher mortality rates and worsened cardiac function compared to infarcted controls (Finger 
et al., 2019). Collectively, these observations indicated that IFN-γ mediates a sequential 
chemotactic cellular immune response that regulates survival and cardiac function. 
On the other hand, administration of IL-10 has been shown to improve left ventricular 
function in rats following MI, which was associated with a significant downregulation of pro-
 
 






inflammatory cytokines and chemokine levels including TNF-α, IL-6, and MCP-1. This effect 
was also accompanied by decreased infiltration of macrophages in the myocardium (Jung et 
al., 2017; Stumpf et al., 2008). Experimental evidence indicates that transcriptional repression 
of monocyte interleukin-10 (IL-10) is mediated through STAT1 signalling (VanDeusen et al., 
2006). Thus, to inhibit the excessive recruitment of monocyte to the infarcted myocardium, 
Wang and co-workers have developed poly(ethylene glycol) (PEG)-distearoylphos-
phatidylethanolamine (PEG-DSPE) micelles loaded with a CCR2 (C-C chemokine receptor 
type 2) antagonist. These micelles were further surface-decorated with an anti-CCR2 antibody 
for efficient targeting. Both non-targeted and CCR2-targeting micelles exhibited a tendency 
to improve cardiac function (Wang et al., 2018). These experiments highlight the crucial 
effects immune cells play in cardiac remodeling post-MI.  
Our results from DESeq2 analysis revealed a set of immune-activating cell markers that were 
differentially expressed at a higher fold change in the early phase post-MI in STAT1-F77A 
mice as compared to their wild-type littermates (Figure 42). In particular, the expression 
profile in the myocardium of STAT1-F77A mice following LAD ligation had identified 
candidate genes involved in chemokines and their receptors, adhesion molecules, cytokines 
and their receptors, growth factors and their receptors, coagulation cascade proteins, and heat 
shock proteins. The top ten differentially upregulated genes in the infarcted myocardium of 
STAT1-F77A mice were Fgf23, Cxcl3, Slfn4, Rab44, Cxcl2, Cd177, Gm5483, Il1r2, Cd300lf, 
and Slfn1.  
Moreover, it is noteworthy to highlight that STAT1-F77A mice had a downregulation in the 
contractile machinery components compared to wild-type mice (Figure 41). This finding 
might be a result of a higher ratio of infiltrating immune cells to cardiac cells in the infarcted 
area, which is essential for cardiac repair processes. This is very interesting in light of 
accumulating research pinpointing to the inflammatory response as a key factor in ventricular 
remodeling, where it is associated with chemokine signalling as well as recruitment and 
migration of different immune cell subsets (Azevedo et al., 2016; Frangogiannis, 2014; Liu et 
al., 2015; Prabhu and Frangogiannis, 2016; Xia and Frangogiannis, 2017).  
To further explore the molecular drivers of myocardial infarction that are under the control of 
STAT1, we performed a gene set enrichment analysis using the results of the DESeq2 
differential expression analysis. Our study in the transgenic mouse line adds to previous 
findings by identifying top downregulated metabolic pathways post-MI, which are oxidative 
phosphorylation, citrate cycle, fatty acid metabolism, fatty acid degradation, and propanoate 
metabolism (Nojiri et al., 2006; Stanton et al., 2000; van Bilsen et al., 2004; Xu et al., 2011). 
 
 






In the present study, we demonstrated a higher decrease in the expression of a multitude of 
genes involved in mitochondrial oxidative phosphorylation, citrate cycle, and substrate 
utilization in the infarcted myocardium in STAT1-F77A mice. These findings are interesting 
given that STAT1 has been identified as a transcriptional modulator of Warburg effect in the 
context of tumorigenesis, regulating genes involved in glycolysis, the citrate cycle and 
mitochondrial oxidative phosphorylation (Pitroda et al., 2009). 
It is important to point out that the highest energy yield in the normal heart comes from 
metabolizing and consuming non-carbohydrate substrates, such as fatty acids. However, 
under certain pathological conditions, glucose becomes a preferential substrate in producing 
energy per oxygen consumption. These alterations are driven by an intricate transcriptional 
regulatory network that feeds into factors including substrate availability and workload 
(Nagoshi et al., 2011). Modifications in the oxidative phosphorylation machinery as a result 
of inflammation-induced NF-κB activation culminate in changes in energy requirement to 
support systolic and diastolic function (Gordon et al., 2011; Remels et al., 2018). Indeed, it 
has been suggested that shifting substrate utilization from fatty acids to glucose can improve 
cardiac function and slow the progression of heart failure (Lionetti et al., 2011).  
It has recently been shown that macrophages exhibit distinctive transcriptomic profiles during 
the first week of myocardial infarction. At day 3 post-MI, macrophages displayed an 
upregulation of genes involved in proliferation, phagocytosis, mitochondrial function and 
oxidative phosphorylation, further suggesting an important role for metabolic reprogramming 
in macrophage polarization (Mouton et al., 2018).  
In order to evaluate post-infarction remodeling in a swine model of MI, Yang and co-workers 
have utilized label-free quantitative proteomics and immunohistochemical analyses (Yang et 
al., 2017). Subsequent experiments in their model have shown a significant downregulation 
of proteins involved in energy metabolism, suggesting dysfunctional myocardial energetics 
and mitochondrial impairment in the peri-infarct border zone. Numerous other mitochondrial 
processes were also similarly downregulated, including branched-chain amino acid 
catabolism, β-oxidation, fatty acid metabolism, Krebs cycle, and the formation of iron-sulfur 
clusters (Yang et al., 2017). These results are in line with our observation that MI interferes at 
a global transcriptional level with oxidative phosphorylation. Taken together, these findings 
clearly support that the imbalance of cardiac substrate metabolism plays a significant role in 
the pathogenesis of heart failure (Birkenfeld et al., 2019; Noordali et al., 2018). 
We have postulated that STAT1-F77A mice will demonstrate a similar phenotype as mice 
expressing hyperactive STAT3 with respect to cardioprotective actions. Phillips et al. 
 
 






suggested that STAT3 is conceivably regulating mitochondrial machinery through 
transcriptional regulation or indirect signalling pathways (Phillips et al., 2010). However, 
according to current concepts activated STAT3 enhances mitochondrial oxidative 
phosphorylation and promotes transformation by oncogenic Ras. The observed 
downregulation of oxidative phosphorylation in STAT1-F77A mice may possibly be 
attributed to the dependence of infiltrating immune cells on glycolysis as a major pathway of 
energy production which is essential for the restoration of homeostasis (Buck et al., 2017). 
Our RNA-seq analysis has several limitations as the data indicate the average gene expression 
pattern using millions of cells which can mask biologically relevant signatures between 
different cell types. Therefore, additional studies using single-cell RNA-seq (scRNA-seq) 
technology will be required to overcome this limitation and determine the transcriptional 
program in individual cell populations including cardiomyocytes, fibroblasts, endothelial 
cells, and immune cells with unparalleled resolution (Farbehi et al., 2019).  
Although there are plenty of studies investigating the role of the immune system in 
myocardial infarction (Lai et al., 2019), many aspects of immunological modulation by 
STAT1 and STAT3 in the infarcted heart still require further elucidation. Therefore, the 
overarching aim of the next experiments were to study the balance of STAT1 and STAT3 
activation in murine heart endothelial cells. Several studies have reported STAT1 and STAT3 
playing opposing roles in regulating multiple cellular processes including survival, 
proliferation, motility and inflammation (Avalle et al., 2012). In our data, we observed that 
upon co-stimulation with IFN- and IL-6 in MHEC-5 cells, the RNA expression level of 
STAT1 target genes were reduced as compared to cells stimulated with IFN- only, however, 
the phosphorylation levels of STAT1 and STAT3 were similar in both conditions.  
The results presented here open up new possibilities for analyzing the role of STAT1:STAT3 
heterodimers in modifying signals downstream of the receptor by integrating different signal 
inputs. Sadreev and colleagues recognized the importance of STAT heterodimer species in 
regulating immune responses (Sadreev et al., 2018). The authors postulated that the 
rearrangement of various STAT dimers formed by stimulation with different extracellular 
cytokines can regulate T-cell plasticity. They further suggested that the competing STAT 
complexes can indirectly inhibit each other depending on extracellular cytokine 
concentrations. An interesting aspect of these findings is that they highlight the biological role 
of STAT heterodimeric complexes which have remained enigmatic (Delgoffe and Vignali, 
2013; Sadreev et al., 2018).  
 
 






The focus of my project was then directed towards studying the role of STAT1 and STAT3 
proteins in controlling transendothelial migration and the regulation of the cytoskeletal ERM 
component ezrin in the neutrophil-like HL-60 cell line. In light of their importance in 
ischemic heart disease, neutrophils have been extensively studied, with excessive infiltration 
contributing to adverse cardiac remodeling in the injured myocardium. Accordingly, directing 
detrimental neutrophils away from the site of cardiac injury is an interesting avenue to 
investigate (de Oliveira et al., 2016).  
In a parallel plate flow chamber assay, analysis of STAT1 and STAT3 knockdown HL-60 
cells showed a reduced transendothelial migration across an endothelial monolayer compared 
to control cells. Therefore, STAT1 and STAT3 knockdown highlighted defects in 
neutrophils’ transendothelial migration, as modelled in HL-60 cells. Our original observation 
indicated that ezrin expression levels are lower in STAT1 and STAT3 knockdown HL-60 
cells as compared to control cells following differentiation with DMSO at day 4. The recently 
published paper by Ivetic et al. provided an interesting model for monocyte behavior during 
transendothelial migration. Herein, the authors described a novel physiological function of 
sequential binding of ezrin and moesin to L-selectin, which modulates L-selectin shedding 
and hence protrusion dynamics and polarity. In our data, it is interesting to note that STAT3 
knockdown in HL-60 cells may result in disorganized cell polarity and loose directional 
persistence. These novel data are in agreement with earlier reports, in which STAT3 
knockdown in mouse embryonic fibroblasts resulted in increased Rac1 activity, which 
regulates directional persistence and generation of actin stress fibers, thus inducing a random 
mode of migration (Teng et al., 2009). The authors have also established a direct binding of 
STAT3 to -PIX, which is a known Rac1 activator, suggesting a possible mechanism for 
STAT3 in modulating actin cytoskeleton reorganization and inducing directional movement 
(Teng et al., 2009). Other studies have focused on the role of IL-6 in promoting epithelial-to-
mesenchymal transition and metastatic behavior via STAT3 signalling pathway within the 
context of carcinogenesis (Yadav et al., 2011). Nevertheless, the physiological significance of 
these data is yet to be evaluated within the context of myocardial infarction. These studies 
would pave the way for more sophisticated experiments involving the re-introduction of 
shRNA immune constructs of mutant STAT1-F77A. Alternatively, the more recently 
developed CRISPR/Cas9 platform of gene editing could be used to engineer the F77A 
mutant.  
With recent advancements in STAT1 signalling, current concepts are continually evolving to 
describe the molecular and cellular processes in the failing heart. In concert with prior studies, 
 
 






the observed upregulation of immune cell markers and adhesion molecules and the significant 
decrease in the expression of oxidative phosphorylation genes in STAT1-F77A as compared 
to wild-type mice may be beneficial in the early phase to meet the demands of repair 
processes through metabolic rewiring and immune cells recruitment. Nowadays, a compelling 
body of experimental evidence indicates that innate and adaptive immune cells play a 
fundamental role in cardiac remodeling (Aubert et al., 2013). Certainly, our finding that 
immunity-related pathways are significantly upregulated following myocardial infarction is in 
good agreement with previous studies showing increased expression of genes involved in 
inflammation, chemotaxis, blood agglutination, and immunity in the myocardial tissue of MI-
operated mice (Li et al., 2019). Furthermore, we observed a downregulation of a multitude of 
genes that are involved in ATP production when STAT1 tetramer activity is suppressed. The 
heart fails when its generation or utilization of free energy in the process of contraction is 
inadequate for the cardiac load imposed. These observations may help explain the why 
STAT1-F77A mice are protected from adverse cardiac remodeling. Overall, these results 
provide evidence for a plausible link between interferon signalling and the modulation of 
gene signature related to mitochondrial ATP synthesis. Our findings will encourage further 
investigations to study if these metabolic changes observed at the transcriptional level of the 
entire genome are reflected by parallel changes in the enzymatic activity of the proteins as 
well as the levels of metabolites. Therapeutic interventions which modify substrate utilization 
will be a promising target to optimize cardiac metabolism and function. Hence, investigating 
how does STAT signalling affect the utilization of alternative fuel sources in cardiac cells in 
addition to the major substrates utilized will be of major importance for an understanding of 
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